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Abstract 
Objectives 
         Many complaints have been made by Sudanese doctors about the lack of 
effectiveness of some common medicinal products in spite of their labeled 
manufacturer’s shelf life is still valid. So, the effect of the real storage 
conditions in Sudan on stability of the different dosage forms of drugs 
circulated in Sudan market is needed.  
Dexamethasone was the drug targeted in this study. It is a life saving drug use 
as a potent anti-inflammatory and anti-allergic.In common with all 
glucocorticoid their suppressive action on the hypothalamic-pituitary-adrenal 
axis is greatest and most prolonged when they are given at night. In most 
individuals a single dose of 1 mg of Dexamethasone at night, is sufficient to 
inhibit corticotropin secretion for 24 hours. This is the basis of the ‘overnight 
dexamethasone suppression test' for diagnosing Cushing's syndrome. 
Dexamethasone is also appropriate for conditions where water retention would 
be a disadvantage. A corticosteroid may be used in the management of raised 
intracranial pressure or cerebral oedema that occurs as a result of malignancy; a 
high dose of dexamethasone is generally used. However, a corticosteroid should 
not be used for the management of head injury or stroke because it is unlikely to 
be of benefit and may even be harmful.It is found in different dosage forms in 
Sudan (tablets, injections, oral solutions and ointments) which are stable in 
normal controlled room temperature but when they were exposed to drastic 
conditions they may show changes due to instability.  
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Methodology 
          Samples were collected directly from local agent and the central 
medicine stores (C D S). Samples were analyzed first at zero time, then three 
parallel lines for distribution were done:- 
1- One batch of each drug was stored in stability cabinet (so as to cover the 
analysis needs) at temperature of 30 ºC ± 2 and 70 % ± 5 R H (Registration 
requirement). 
2- The same batch was distributed to different areas in Sudan. These areas 
(Dongola, Port Sudan, Elfashir, Elgadarif and Khartoum) were selected so as 
to cover the different climatic conditions in Sudan. The distribution was 
done using controlled temperature vehicles and then stored at actual storage 
conditions found in local pharmacies. Samples were collected at the time of 
test and send by controlled temperature vehicles as follows:- 
• After 4 month of storage. 
• After 8month of storage. 
• After12 month of storage. 
3. The same batch was stored in well controlled conditions (local agents drug 
stores). 
             Samples were analyzed using the USP (30) methods. The results 
obtained from stability cabinet were compared with those obtained from the 
different areas of Sudan and those obtained from the controlled conditions. 
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Results:- 
As show in table No (1) :- 
(1) Dexamethasone sodium phosphate injection:- 
The assay results obtained after follow up for one year from different areas in 
Sudan showed changes between 20.0% - 25.0%, while samples stored at 
C.D.S. showed about 3.2% changes. 
The pH changes were between 0.30 - 0.70. 
(2) Dexamethasone tablets :- 
         The assay results obtained after follow up for one year from different 
areas in Sudan showed changes between 6.8 % -14.8 %   while samples 
obtained from another company showed about 13.8% - 13.9% changes in 
both company stores and pharmacy through 6 month.   
        The dissolution test results showed an increase in U.V. reading after 4 
month due to the degradation product which absorb at the same wavelength . 
 (3) Dexamethasone ointments :- 
         The assay results obtained after follow up for one year from different 
areas in Sudan showed between 1.0% - 12.5% changes . 
 (4) Dexamethasone oral solution :- 
       The assay results obtained after follow up for one year from different 
areas in Sudan showed between 34.6 %- 37.3% changes, while samples 
stored at company store showed about 5.7% changes. 
    The pH changes were between 0.3 - 0.4 
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Conclusion 
          The different dosage forms of dexamethasone (tablets, ointments, oral 
solutions and injections) were clearly affected when exposed to the real storage 
conditions in the market comparing with those stored in controlled storage 
conditions. This indicate that the storage conditions in the market is not suitable for 
these dosage forms to remain stable over its shelf life.    
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  اﻻﻃﺮوﺣﻪ ﻣﺴﺘﺨﻠﺺ
  
 
  :اﻷهﺪاف
 ﺔﺻﺎﻟﺤﻧﺘﻴﺠﺔ ﻟﻠﺸﻜﺎوى اﻟﻤﺘﻜﺮرة ﻣﻦ اﻷﻃﺒﺎء ﻓﻴﻤﺎ ﻳﺨﺺ ﻓﻌﺎﻟﻴﺔ اﻷدوﻳﺔ ﺑﺎﻟﺮﻏﻢ ﻣﻦ أﻧﻬﺎ ﻻ ﺗﺰال            
هﻮ ﻣﻮﺿﺢ ﻋﻠﻰ اﻟﺪﻳﺒﺎﺟﺔ آﺎن ﻻ ﺑﺪ ﻣﻦ دراﺳﺔ ﺗﺄﺛﻴﺮ ﻇﺮوف اﻟﺘﺨﺰﻳﻦ اﻟﺤﻘﻴﻘﻴﺔ  اﻟﺘﻲ ﺎ ﻟﻼﺳﺘﻌﻤﺎل ﺣﺴﺐ ﻣ
  رﻟﻘﺪ ﺗﻢ اﺧﺘﻴﺎر ﻋﻘﺎ .ﻟﻤﺨﺘﻠﻔﺔﺑﺄﺷﻜﺎﻟﻬﺎ اﻟﺼﻴﺪﻻﻧﻴﺔ ا ﺔدوﻳاﻷ ﺛﺒﺎﺗﻴﺔﻳﺘﻌﺮض ﻟﻬﺎ اﻟﺪواء ﻓﻲ اﻟﺴﻮدان ﻋﻠﻰ 
  اﻟﺼﻴﺪﻻﻧﻴﺔ اﻟﻤﺨﺘﻠﻔﺔ اﻟﻤﻮﺟﻮدة ﻓﻲ اﻟﺴﻮق اﻟﻤﺤﻠﻰ ﻣﺜﻞ ﻪاﻟﺪآﺴﺎﻣﻴﺜﺎزون ﻓﻲ هﺬﻩ اﻟﺪراﺳﺔ ﻣﻤﺜﻼ ﻓﻰ اﺷﻜﺎﻟ
و ذﻟﻚ ﻷﻧﻪ ﻋﻘﺎر ﻣﻨﻘﺬ ﻟﻠﺤﻴﺎة و ﻳﺴﺘﺨﺪم ﻓﻲ ﻋﻼج ﺣﺎﻻت آﺜﻴﺮة آﻤﻀﺎد  ﺑﺎتااﻟﺤﻘﻦ واﻟﺸﺮ ,اﻟﻤﺮاهﻢ  ،اﻻﻗﺮص
ﺮوف أن اﻟﺪآﺴﺎﻣﻴﺜﺎزون ﺛﺎﺑﺖ ﻓﻲ ﻇﺮوف اﻟﺘﺨﺰﻳﻦ اﻻﻋﺘﻴﺎدﻳﺔ ﻣﻦ اﻟﻤﻌ  .ﻟﻼﻟﺘﻬﺎﺑﺎت وﻣﻀﺎد ﻟﻠﺤﺴﺎﺳﻴﺔ
 دونﻟﻈﺮوف  ﺗﺨﺰﻳﻦ  اﻟﻤﻨﺼﻮص ﻋﻠﻴﻬﺎ ﻓﻲ اﻟﺪﻳﺒﺎﺟﺔ ﺑﻴﻨﻤﺎ ﻳﻈﻬﺮ ﺗﻐﻴﺮات ﺗﺪل ﻋﻠﻰ ﻋﺪم اﻟﺜﺒﺎت ﻋﻨﺪ ﺗﻌﺮﺿﻪ
آﺎن ﻻ ﺑﺪ اﻟﻤﻮاﺻﻔﺎت وﻧﺴﺒﻪ ﻟﺘﺒﺎﻳﻦ ﻇﺮوف اﻟﻤﻨﺎخ ﻣﻦ ﻣﻨﻄﻘﻪ ﻷﺧﺮى ﻓﻲ اﻟﺴﻮدان ﻣﻤﺎ ﻗﺪ ﻳﺆﺛﺮ ﻋﻠﻰ ﺛﺒﺎت اﻟﺪواء 
   .ﺪراﺳﺔﻟإﺟﺮاء هﺬﻩ اﻣﻦ 
    :اﻟﻄﺮﻳﻘﺔ
  -: و ﻣﻦ ﺗﻢ ﺗﻮزﻳﻌﻬﺎ ﻋﺒﺮ ﺛﻼﺛﺔ ﻗﻨﻮات (اﻟﻮآﻴﻞ ﺑﺎﻟﺴﻮدان أو اﻹﻣﺪادات اﻟﻄﺒﻴﺔ) ﺗﻢ ﺗﺠﻤﻴﻊ اﻟﻌﻴﻨﺎت ﻣﻦ ﻣﺼﺎدرهﺎ 
ورﻃﻮﺑﺔ (  2 ± 03 C˚)   ةﺟﺮاء دراﺳﺎت اﻟﺜﺒﺎت ﻓﻰ درﺟﺔ ﺣﺮارﺔ ﻹﻣﺨﺼﺼ وﺿﻌﺖ اﻟﻌﻴﻨﺎت ﻓﻲ ﺣﻀﺎﻧﺔ - 1
  (. 03) اﻟﻮاردة ﻓﻲ دﺳﺘﻮر اﻷدوﻳﺔ اﻻﻣﺮﻳﻜﻰﺛﻢ ﺗﻢ ﺗﺤﻠﻴﻠﻬﺎ وﻓﻖ ﻃﺮق اﻟﺘﺤﻠﻴﻞ  (5±% 07  )ﻧﺴﺒﻴﺔ 
  ﺷﻤﻠﺖ آﻞ ﻣﻦ   ﻣﻨﺎﺣﺎت ﻣﺘﺒﺎﻳﻨﺔ ذات وزﻋﺖ ﻧﻔﺲ اﻟﺘﺸﻐﻴﻼت ﻋﻠﻰ ﻣﻨﺎﻃﻖ - 2
ﺑﺤﻴﺚ ﺗﻢ ﺗﺨﺰﻳﻨﻬﺎ داﺧﻞ اﻟﺼﻴﺪﻟﻴﺎت اﻟﻌﺎﻣﺔ ﺑﺘﻠﻚ اﻟﻤﻨﺎﻃﻖ  ﺑﻮر ﺗﺴﻮدان واﻟﻔﺎﺷﺮ ،اﻟﻘﻀﺎرف ،دﻧﻘﻼ، اﻟﺨﺮﻃﻮم 
وﻗﺪ  ﻓﻪ ﺗﺄﺛﻴﺮهﺎ ﻋﻠﻰ ﺛﺒﺎت و ﻓﻌﺎﻟﻴﺔ اﻷدوﻳﺔﺑﺎﻟﺘﺎﻟﻲ ﻧﺘﻤﻜﻦ ﻣﻦ ﻣﻌﺮﺗﺘﻌﺮض ﻟﻈﺮوف اﻟﺘﺨﺰﻳﻦ اﻟﺤﻘﻴﻘﻴﺔ و ﺑﺤﻴﺚ
 -: آﻤﺎ ﻳﻠﻰﺗﻢ ﺗﺤﻠﻴﻠﻬﺎ 
  ﺑﻌﺪ  4  .ﻣﻦ اﻟﺘﺨﺰﻳﻦأﺷﻬﺮ 
  ﺑﻌﺪ  8 .ﻣﻦ اﻟﺘﺨﺰﻳﻦ أﺷﻬﺮ  
  ﺑﻌﺪ  21  .ﻣﻦ اﻟﺘﺨﺰﻳﻦ ﺷﻬﺮ 
           ﻧﻔﺲ اﻟﺘﺸﻐﻴﻼت ﺗﻢ ﺗﺨﺰﻳﻨﻬﺎ ﻓﻲ ﻣﺨﺎزن ﻳﻮﺟﺪ ﺑﻬﺎ ﺗﺤﻜﻢ ﻓﻲ درﺟﺎت اﻟﺤﺮارة واﻟﺮﻃﻮﺑﺔ وﻗﺪ ﺗﻢ ﺗﺤﻠﻴﻠﻬﺎ ﺑﻌﺪ - 3
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  ﺞﺋاﻟﻨﺘﺎ
 ﻦاﻟﺤﻘ
أﻇﻬﺮت ﻧﺘﺎﺋﺞ اﻟﺘﺤﻠﻴﻞ ﻟﻌﻴﻨﺎت اﻟﺪآﺴﺎﻣﻴﺜﺎزون ﻣﻦ اﻟﻤﻨﺎﻃﻖ اﻟﻤﺨﺘﻠﻔﺔ ﻋﻨﺪ ﻣﺘﺎﺑﻌﺘﻬѧﺎ ﻟﻤѧﺪة ﻋѧﺎم أن ﻧﺴѧﺒﺔ اﻟﺘﻐﻴѧﺮ 
  .%2.3ﺑﻴﻨﻤﺎ ﻧﺴﺒﺔ اﻟﺘﻐﻴﺮﻓﻰ اﻟﻌﻴﻨﺎت اﻟﻤﺤﻔﻮﻇﺔ ﻓﻲ ﻣﺨﺎزن اﻹﻣﺪادات هﻲ .%0.52 - %0.02 ﺗﺘﺮاوح ﺑﻴﻦ
   7.0 -3.0اﻟﺘﻐﻴﺮ ﻓﻲ درﺟﺔ اﻷس اﻟﻬﻴﺪروﺟﻴﻨﻲ ﻳﺘﺮاوح ﺑﻴﻦ
  ﻷﻗﺮاصا
أﻇﻬѧﺮت ﻧﺘѧﺎﺋﺞ اﻟﺘﺤﻠﻴѧﻞ ﻟﻌﻴﻨѧﺎت اﻟﺪآﺴѧﺎﻣﻴﺜﺎزون ﻣѧﻦ اﻟﻤﻨѧﺎﻃﻖ اﻟﻤﺨﺘﻠﻔѧﺔ ﻋﻨѧﺪ ﻣﺘﺎﺑﻌﺘﻬѧﺎ ﻟﻤѧﺪة ﻋѧﺎم أن ﻧﺴѧﺒﺔ     
 ﺑﻴﻨﻤﺎ ﻧﺴﺒﺔ اﻟﺘﻐﻴﺮﻓﻰ اﻟﻌﻴﻨﺎت اﻟﻤﺎﺧﻮذﻩ ﻣѧﻦ ﺷѧﺮآﻪ أﺧѧﺮى هѧﻲ  % 8.41 - %8.6   ﺗﺘﺮاوح ﺑﻴﻦ    اﻟﺘﻐﻴﺮ 
 .أﺷﻬﺮﺧﻼل ﺳﺘﺔ  %9.31-8.31%
 ﻓѧﻲ اﻟﻘѧﺮاءات ﺑﻌѧﺪ أرﺑﻌѧﻪ أﺷѧﻬﺮﻧﺘﻴﺠﻪ ﻻن  ةﻴﺔ ﻓﻘѧﺪ أﻇﻬѧﺮت زﻳѧﺎدة آﺒﻴѧﺮ أﻣﺎ ﻓﻴﻤﺎ ﻳﺨﺺ ﻧﺘﺎﺋﺞ اﺧﺘﺒﺎر اﻻﻧﺤﻼﻟ
 .ﺟﻪﻳﻌﻄﻰ ﻗﺮاءة ﻓﻲ ذات اﻟﻤﻮ  ﻧﺎﺗﺞ ﺗﻔﻜﻚ اﻟﺪواء
  اﻟﻤﺮاهﻢ
أﻇﻬѧﺮت ﻧﺘѧﺎﺋﺞ اﻟﺘﺤﻠﻴѧﻞ ﻟﻌﻴﻨѧﺎت اﻟﺪآﺴѧﺎﻣﻴﺜﺎزون ﻣѧﻦ اﻟﻤﻨѧﺎﻃﻖ اﻟﻤﺨﺘﻠﻔѧﺔ ﻋﻨѧﺪ ﻣﺘﺎﺑﻌﺘﻬѧﺎ ﻟﻤѧﺪة ﻋѧﺎم أن ﻧﺴѧﺒﺔ     
  .. % 5.21 - %0.1اﻟﺘﻐﻴﺮ ﺗﺘﺮاوح ﺑﻴﻦ
  
  :ﺑﺎتااﻟﺸﺮ
أﻇﻬﺮت ﻧﺘﺎﺋﺞ اﻟﺘﺤﻠﻴﻞ ﻟﻌﻴﻨﺎت اﻟﺪآﺴѧﺎﻣﻴﺜﺎزون ﻣѧﻦ اﻟﻤﻨѧﺎﻃﻖ اﻟﻤﺨﺘﻠﻔѧﺔ ﻋﻨѧﺪ ﻣﺘﺎﺑﻌﺘﻬѧﺎ ﻟﻤѧﺪة ﻋѧﺎم أن ﻧﺴѧﺒﺔ       
 %7.5 ﻓﻰ اﻟﻌﻴﻨﺎت اﻟﻤﺤﻔﻮﻇﺔ ﻓﻲ ﻣﺨﺎزن اﻟﺸﺮآﺔ ﺑﻴﻨﻤﺎ ﻧﺴﺒﺔ اﻟﺘﻐﻴﺮ % 6.43 - %3.73.   اﻟﺘﻐﻴﺮ ﺗﺘﺮاوح 
   4.0 -3.0اﻟﺘﻐﻴﺮ ﻓﻲ درﺟﺔ اﻷس اﻟﻬﻴﺪروﺟﻴﻨﻲ ﻳﺘﺮاوح ﺑﻴﻦ
  :اﻟﺨﻼﺻﺔ
ﺪراﺳѧѧﺔ ﺗѧѧﺪهﻮرا واﺿѧѧﺤﺎ ﻓѧѧﻲ ﻣﺤﺘѧѧﻮى اﻟﻤѧѧﺎدة اﻟﻔﺎﻋﻠѧѧﺔ ﻓѧѧﻲ  اﻷﺷѧѧﻜﺎل اﻟﺼѧѧﻴﺪﻻﻧﻴﺔ اﻟﻤﺨﺘﻠﻔѧѧﺔ ﻣѧѧﻦ أﻇﻬѧѧﺮت اﻟ
اﻟﺪآﺴѧﺎﻣﻴﺜﺎذون اﻟﻤﺨﺰﻧѧﺔ ﻓѧﻲ ﻇѧﺮوف اﻟﺘﺨѧﺰﻳﻦ اﻟﺤﻘﻴﻘﻴѧﺔ ﻓѧﻲ ﻣﻨѧﺎﻃﻖ اﻟﺴѧﻮدان اﻟﻤﺨﺘﻠﻔѧﺔ ﻋﻨѧﺪ ﻣﻘﺎرﻧﺘﻬѧﺎ ﺑﺘﻠѧﻚ 
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1. 1.Definitions:- 
1.1.1. Drug product:- 
           The dosage form in the final immediate packing intended for marketing. 
1.1. 2.Excipients:- 
           Any thing other than the drug substance in the dosage form. 
1.1.3. Active substance:- 
      The unformulated drug substance which may be subsequently formulated with 
excipients to produce drug substance. 
1.1.4. Dosage forms:- 
       A pharmaceutical product type that contains a drug ingredient generally, but not 
necessarily in association with excipients. 
1.1.5. Expiry date:- 
       Date placed in the container/labels of drug product designating the time during 
which a batch of the product is expected to maintain within specifications. 
1.1.6. Storage condition tolerance:- 
        The acceptable variation in temperature and relative humidity of storage 
facilities (± 2C˚ for temperature and ± 5% for humidity).     
  (Jens T. Carstensen second edition). 
1.1.7. Tablets:- 
          Tablets are solid preparations each containing a single dose of one or more 
active substances and usually obtained by compressing uniform volumes of 
particles. Tablets are intended for oral administration .Some are swallowed whole, 
some after being chewed ,some are dissolved or dispersed in water before being 
administered and some are retained in mouth where the active substance liberated. 
 - 3  - 
 
         The particles consist of one or more active substance with or without exipients 
such as diluents, binders, disintegrating agents, glidants, lubricants, substances 
capable of modifying behavior of preparation in digestive tract ,coloring matter 
authorized by the competent authority and flavoring substances. 
       Tablets are usually right, circular solid cylinders, the end surface of which are 
flat or convex and edges of which may be bevelled .They may have break-marks or 
may bear a symbol or other markings. Tablets may be coated.      
    1.1.8. Injections:- 
        Parental preparations are defined as solutions, emulsions in water for 
injections, and does not preclude the inclusion of suitable excipients where 
necessary. In particular, aqueous parental preparation for administration by 
subcutaneous, intradermal, intramuscular, or in case of larger volumes, intravenous 
rout, should, if possible, be made isotonic with blood by addition of sodium chloride 
or a suitable substances .However if buffering agents are used in preparations 
intended for intraocular or intracardiac injection or  in preparations that may gain 
access to cerebrospinal fluid, great care should be taken to ensure that the nature and 
concentration of chosen agent are suitable for the intended rout of administration . 
Where the active ingredient is susceptible to oxidative degradation appropriate 
precautions should be taken.         
1.1.9. Oral liquids:- 
        Liquid preparations for oral use are usually solutions, emulsions or suspensions 
containing one or more active substances in suitable vehicle, they may, however 
consist of liquid active substances used as such. 
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       The vehicle for many preparations for oral use is chosen having regard to the 
nature of the active substance and to provide organoleptic characteristics appropriate 
to the intended use of the preparation. 
        Oral liquids may contain suitable antimicrobial preservatives, antioxidants and 
other excipients.   
(The British pharmacopoeia commission, 2009) 
1.10. Ointments:- 
Ointments are semisolid preparations intended for external application to the skin or 
mucous membranes. 
       Ointments bases recognized for use as vehicle fall into four general classes: the 
hydrocarbon bases, the absorption bases, the water removable bases, and the water 
soluble bases .Each therapeutic ointment possesses as its base a representative of 
one of these four general classes.  
(United states pharmacopoeia convention 30 NF)         
1.2. Drug stability:- 
           A medicinal product is designed to possess certain desirable properties of 
which the following are of major importance:- 
When the product is administered by the specified route, the active 
constituent should achieve the required rate and extent of bioavailability. 
              The product itself should be efficacious, safe and acceptable to the patient; it 
should be convenient in use and stable.  
(Walter Lund 12 edition)  
         Stability of pharmaceutical product may be defined as the capability of 
particular formulation (in specific container/closure system) to remain within its 
physical, chemical, microbiological, therapeutic and toxicological specification. 
 - 5  - 
 
(Remington pharmaceutical sciences 17th edition 1985 ) 
        There are many factors that affect the stability of pharmaceutical products, 
including the stability of active ingredients, the potential interaction between active 
and inactive ingredients, the manufacturing process, the dosage form, the container 
liner- closure system, the environmental conditions encountered during shipment, 
storage, handling and length of time between manufacture and usage.  
 (Remington pharmaceutical sciences 17th edition 1985) 
        The term stability with respect to the drug dosage form refers to the physical 
and chemical integrity of the dosage unit and when appropriate, the ability of dosage 
unit to maintain protection against microbiological contamination. The stability can 
be influenced by environmental conditions of storage (temperature, light, air and 
humidity). 
 (United states pharmacopoeia convention 24) 
        Stability is often expressed in quantitative terms as the shelf life: that is the 
time during which the medicinal product is predicted to remain fit for its intended 
use under specified condition of storage. The shelf life of medicinal product kept in 
its closed container under specified conditions is commonly defined as the time  
from manufacturing or preparation until the original potency or content of active 
constituents has been reduced by  10%.This time is known as (t10%) . This 10% limit 
of chemical degradation is usually considered to be acceptable in practice but more 
stringent limits may need to be imposed if degradation products are more toxic or 
irritant than is the drug. Although it is often convenient to express shelf life solely in 
terms of chemical stability of active constituent, it is essential that the other 
desirable properties of the product are retained during storage. 
(Walter Lund 12 edition)   
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 1.2.1 Types of drug stability:- 
1.2.1.1. Chemical stability. 
1.2.1.2. Physical stability.  
1.2.1.3. Microbiological stability. 
1.2.1.1Chemical stability:- 
            Chemical degradation of the active constituent in a medicinal product often 
results in loss in potency .The degradation products of drugs may be very toxic (for 
example epianhydrotetracycline formed from tetracycline ) so that clinical use of 
preparation may be unacceptable if the extent of decomposition is relatively great . 
Degradation of an excipient can pose problems of physical or microbiological stability 
(for example hydrolysis of sorbitan ester may result in sufficient loss in its stability to 
produce an interfacial film that a formulated emulsion may crack ). Since chemical 
reaction proceed more readily in liquid state than in the solid state, then solid dosage 
forms are of greater stability than others   . 
 (Walter Lund 12 edition ) 
1.2.1.1.1.Factors that may affect chemical stability :- 
                  The rate of chemical reaction of a drug or excipient in a medicine may be 
affected by physicochemical factors such as :-  
1.2.1.1.1.1.pH :- 
              In reversible oxidations the standard reduction potential may depend on pH; 
thus pH may affect the tendency of a drug to be oxidized. 
             Hydrolysis reactions are often catalyzed by both hydrogen ions and 
hydroxide ions. Since hydroxide usually exert a greater catalytic effect than 
hydrogen ions, the minimum degradation rate (the maximum stability ) of many 
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drugs is  in the range of pH  2 to 5 . In addition temperature may modify the e0ffects 
of pH. 
           The rate of other reactions such as isomerisation may be influenced by   pH. 
1.2.1.1.1.2.General acids and bases :- 
         In addition to catalysis by hydrogen ions and hydroxide ions (specific acid - 
base catalysis), certain hydrolysis reactions are catalyzed by other acidic and 
basic species  
(General acid - base catalysis) such as those salts used to buffer solutions of drugs. 
1.2.1.1.1.3.Ionic strength :- 
                 Addition of an inert electrolyte to an aqueous solution of drug may 
exert a direct effect on stability even though there is no chemical interaction 
between the drug and the electrolyte (primary salt effect) which depend on the 
concentration of the added salt and on the charges born by the reacting ions. If 
ions bear the same charge, the addition of salt increases the rate of degradation. 
In contrast, when ions are of opposite charge, the rate is decreased. When one of 
the reactant is not charged, addition of a salt should not affect stability of the 
drug. 
              Electrolytes may also indirectly influence the rate of reaction by 
modifying the ionization constant of week acids or bases present in buffer 
solutions and enhancing or reducing catalysis by general acids and bases 
(secondary salt effect). 
1.2.1.1.1.4.Nature of solvent :- 
               The influence of the solvent on the rate of degradation of a drug 
depends largely on the dielectric constant of solvent and on the electrical charge 
on the drug .When the charge on the drug and attacking ion are the same , part or 
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complete replacement of water(high dielectric constant) by alcohol ,propylene 
glycol ,or glycerol(lower dielectric constants) usually lowers the rate of 
degradation . Where the charge are opposite reduction in dielectric constant of 
solvent would be expected to increase the rate of degradation. 
 (Walter Lund 12 edition) 
1.2.1.1.1.5.Drug concentration :- 
                The effects of drug concentration on degradation depend on the order 
of reaction. For example, if the reaction follows first – order kinetics, the rate is 
directly proportional to drug concentration but the time for certain proportion to 
decompose is independent of concentration. 
               Where the mechanism of degradation and order reaction depend on 
drug concentration, the kinetic are complex. In dilute solution, ampicillin 
degrades by pseudo- first order kinetics but in more concentrated solutions the 
reaction becomes third order, concentrated solution of this drug degrade more 
rapidly than dilute solutions. . 
 (Walter Lund 12 edition) 
              For degradation of drugs where the molecules associate to form micelles 
,the order of reaction may depend on drug concentration ;for example the thermal 
degradation in dark of promethazine hydrochloride in aqueous solution appeared 
to follow first order kinetics at concentrations below 0.5% but zero order kinetics 
at concentrations above 3.0%  
(Meakin B J ,etal, 1978)  
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1.2.1.1.1.6.Surfactants :- 
            Surfactants are used as excipients in the formulations of medicines, 
especially as dispersing emulsifying or solubilising agents. The effects of 
surfactants on the stability of drugs may depend on factors such as concentration, 
solubility, chemical nature, and chain length of the surfactant, the mechanism of 
degradation of the drug, its site of solubilisation, and the charge on the attacking 
ion. 
               The auto-oxidations of the oil methyl linoleate in simple dispersion in 
water was very slow because very little oil was soluble; addition of potassium 
laurate results in formation of an emulsion in which part of the methyl lineate 
was solubilised in micelles of the surfactant and part was present as oil droplets. 
Autoxidations of the emulsion was rapid since the micelles provided especially 
favorable conditions for initiation of the reaction; the free radicals formed then 
migrated from the micelles into the water and diffused into oil droplets where 
propagation proceeded rapidly. Further addition of the surfactant resulted in 
more oil molecules becoming solubilised until the solubilisation process was 
complete; at this stage, the rate of auto-oxidation was much lower because there 
were no oil droplets present to enable rapid propagation to occur ; at high 
concentrations of the surfactant the auto-oxidation rate was further reduced; this 
effect was attributed to a smaller number of methyl linoleate in each micelle.   
(Carless JE and Nixion JR.J 1960)  
 
 
 
 
 - 10  - 
 
1.2.1.1.1.7.Peroxides :- 
               The presence of highly labile peroxides may catalyze the initiation and 
propagation stages of auto-oxidation since these substances easily form free 
radicals. Peroxides are commonly formed in fixed oils and in diethyl ether. 
(  Walter Lund 12 edition) 
1.2.1.1.1.8.Heavy metal ions :- 
                Traces of heavy metals ions often catalyze auto-oxidation reaction. The 
mechanism of action of heavy metals is demonstrated by shortening of the lag 
phase. The mechanism of action of heavy metals ions appears to be associated 
with the rapid formation of free radicals and is thought to be due to the ability of 
such cations to change readily from one valency state to another: for example, 
cupric to cuprous. Sources of heavy metal ions include metal manufacturing 
equipment, water, drugs of natural origin excipients, and chromic acid used for 
cleaning of glassware.  
1.2.1.1.1.9.Oxygen:- 
                 Many oxidation reactions that occur in the ingredients of medicines 
are autoxidations where oxygen is necessary for propagation of the chain 
reaction. Often a low concentration of oxygen in the product is sufficient to 
permit considerable oxidation to take place. The partial pressure of oxygen in the 
air in container may be important. 
1.2.1.1.1.10.Carbon dioxide :- 
                 The partial pressure of gaseous carbon dioxide in the container or its 
concentration in the product may affect the rate and extent of reactions that 
involve the uptake of this gas. 
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1.2.1.1.1.11.Water :- 
                  Drug substances, excipients, and solid dosage forms such as tablets 
and capsules may contain small amount of water .Since substances and solid 
dosage forms are sometimes kept at a relatively high humidity they may sorbs 
water on the surface which may lead to dissolution of the drug and to 
degradation. 
 (Walter Lund 12 edition) 
                 In a study of aspirin stability in solid state the degradation depended on 
water vapor pressure .The mechanism is that water is rapidly sorbed as a monolayer 
or multilayer on the surface of the drug particles ; The amount sorbed is a function 
of water vapor pressure . Some of aspirin then dissolves in the sorbed water to form 
a saturated solution; as aspirin in solution hydrolyses to acetic and salicylic  acid  
,more of the solid aspirin dissolves so that the solution remains saturated . 
( Leeson LJ ,and Maddocks AM. 1958). 
1.2.1.1.1.12.Temperature :- 
                For many reactions an increase in temperature enhances the rate 
constant (Arrhenius equation).Information on the effect of temperature is 
important in the prediction of shelf life of products marketed in the tropics .The 
effect of temperature on some oxidation reactions may operate in opposing 
directions, although a rise in temperature results in a higher degradation rate, it 
also decrease the solubility of oxygen in water so affects the rate of oxidation 
(Do not follow the Arrhenius equation).   
               Storage at low temperatures may adversely affect the stability of some 
medicines for example: polymerization of formaldehyde in aqueous solution 
proceeds more rapidly below 15˚.  (Walter Lund 12 edition) 
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1.2.1.1.1.13.Light :- 
                   Photochemical reactions involve the absorption of light of particular 
wave length in the ultraviolet or visible regions of the spectrum. The radiant 
energy must exceed a threshold before the reaction can occur .However not all 
absorbed light leads to reaction, since some may be converted to heat or 
transferred to molecules of another substance, or emitted at the same or different 
wave length .As the wave length increases there is a decrease in radiant energy. 
1.2.1.1.1.14.Ionizing Radiation :- 
                 The use of ionizing radiation to sterilize medicinal products may result 
in decomposition. At the radiation dose (25 KGY) commonly recommended for 
sterilization, the nature and extend of degradation of many substances is 
unacceptable. 
1.2.1.1.1.15.Mechanical processes :- 
                 Grinding can cause drug solvates or hydrates to become more 
chemically unstable since it weaken the bonding force between drug molecule 
and its water of crystallization; thus liberated water molecules can take part in 
hydrolysis reaction.  
(Walter Lund 12 edition) 
1.2.1.2.2.Reactions that cause chemical degradation:- 
       A variety of chemical reactions can result in the degradation of drug substances 
and excipients; sometimes more than one reaction may occur at the same time 
.These reactions are:- 
1.2.1.1.1.1.Hydrolysis :-  
       For most parenteral products, the drug comes into contact with water and, even 
in solid dosage forms; moisture is often present, albeit in low amounts. Accordingly, 
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hydrolysis is one of the most common reactions seen with pharmaceuticals. 
Hydrolysis is often the main degradation pathway for drug substances having ester 
and amide functional groups within their structure. It involves the reactions of 
molecules with water that results in cleavage.  
        Enzyme catalyzed hydrolysis may take place in drugs of natural origin. 
(Sumie Yoshioka and Valentino J. Stella) 
1.2.1.1.1.2.Dehydration :- 
Dehydration reaction occurs occasionally in drugs. 
1.2.1.1.1.3.Oxidation :- 
           Oxidation is applied to reactions in which either one or more electropositive 
atoms, radicals or electrons are lost or more electronegative atoms or radicals are 
gained .Many drugs are prone to degrade by oxidation. Oxidation reactions are 
either redox reactions without addition of oxygen (reversible) or chain reaction in 
which a substance becomes slowly oxidized in the presence of atmospheric oxygen.  
 (Walter Lund 12 edition). 
1.2.1.1.1.4. Isomerisation :-   
Isomerisation is the conversion of a substance into its geometric or optical isomers; 
these have the same structural formula but differ in astrochemical configuration. 
           1.2.1.1.1.4.1.   Geometric Isomerisation: - This conversion involves 
changes in the relative spatial configuration of atoms or groups around ethylene 
double bonds or cyclic compounds .Different geometric isomers may possess 
different potencies. 
           1.2.1.1.1.4.2. Optical Isomerisation: - It is change in the optical rotation of 
substance as a result of presence of one or more chiral centers. Two types of optical 
isomerisation can be distinguished: Racemisation and Epimerization.  
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             1.2.1.1.1.4.3. Racemisation:- 
      Racemisation involves the conversion of an optically active drug with one chiral 
center into an isomer whose structure is a mirror image of the original molecule 
(Enantiomers ). The reaction continues until the concentration of the two 
enantiomers are equa. At this stage the solution of the resultant racemic mixture no 
longer rotates the plane of polarized light . Racemisation of some drugs may lead to 
more complex pharmacological or toxicological effects for example: enantiomers 
may differ in their affinity for receptors or may have opposite effects. 
  1.2.1.1.1.4.4.  Epimerization:- 
          Occurs when there is more than one chiral center in which there is selective 
racemisation at one center; the equilibrium between the two epimers may not 
represent equal concentrations of each since the presence of other chiral centers may 
favour the formation of one epimer rather than the other so the optical rotation of the 
two isomers are not equal and opposite so the optical activity of the mixture of 
epimers at equilibrium will not be zero. 
 (Walter Lund 12 edition page) 
1.2.1.1.1.5.polymerization :- 
              It is the combination of two or more identical molecules of substance to 
form more complex molecule, often polymerization follows a primary degradation 
process. 
1.2.1.1.1.6.Photochemical reaction :- 
              When exposed to light many drugs and excipients are susceptible to 
degradation by a variety of photochemical reactions (oxidation, reduction). 
           In a photochemical reaction, the light-sensitive drug molecules may be 
affected directly or indirectly by light, depending upon how the absorbing photon 
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energy is transferred to the drug molecules. With a direct or indirect light-induced 
reaction, a drug can only undergo the photo-degradation process if the absorbed 
energy exceeds a threshold. Because ultraviolet radiation has higher energy, it is the 
main cause of many degradation reactions of light-sensitive drugs. Colored-glass 
containers are the most commonly used method to protect these types of drugs. 
Yellow-green glass gives the best protection in the ultraviolet region; amber glass 
also offers considerable protection from ultraviolet light, but little protection from 
infrared light. 
The photochemical reaction is a very complex process; many variables may be 
involved in the photolytic degradation kinetics. The velocity of the photochemical 
reaction may be affected not only by the light source, intensity, and wavelength of 
the light, but also by the size, shape, composition, and color of the container. To 
properly determine the effects of light on the quality of a drug properly, standard 
light stability testing should consider all of the aforementioned variables. Once 
uniform standard light-stability testing procedures are instituted, proper packaging, 
storage environment, and expiration date for the light-sensitive drug can be 
established. 
(Hanne Hjorth Tonnsen, 2004) 
1.2.1.1.1.7.Radiation - induced reaction :- 
             Degradation by complex mechanisms due to exposure to ionizing radiation. 
1.2.1.1.1.8.Decarboxylation :- 
It is removal of carbon dioxide from substance .It may occur as primary reaction  or 
as a secondary degradation reaction (for example procaine hydrochloride hydrolysis 
to form 4-amino benzoic acid which Decarboxylates to form aniline. 
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1.2.1.1.1.9.Absorption of carbon dioxide :- 
           Absorption of carbon dioxide lead to lower the pH and the free acid form is 
precipitated .As in solutions of calcium hydroxide. 
 (Walter Lund 12 edition) 
1.2.1.3. Order of reaction: 
                       It is the way in which concentration of reactant, or reactants, 
influences the rate of chemical reaction. 
1.3.1. First order reaction: 
                     The rate of a reaction is proportional to the first power of the 
concentration of a reactant and may be expressed mathematically as follow : 
- dc /dt = Kc 
When log c was plotted against (t) it will gave straight line; and the values of K, t10, 
t50 was expressed as follow: 
K = 0.693/slop 
t10 = 0.105/K 
t50 = 0.693/K 
1.3.2. Second order reaction: 
                  The rate of a reaction is proportional to concentration of each of two 
reactant or the second power of the concentration of one reactant and may be 
expressed mathematically as follow: 
- dcA/dt =-dcB/dt = K.cA cB 
t50  OR  t 1/2 =1/K a 
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1.3.3. Zero order reaction: 
             The rate is independent of concentration of reactants. In such cases the rate 
is expressed as: 
- dc/dt =K 
And t10, t50 was expressed as follow: 
t10 = 0.1a/K 
t50 = 0.5a/K 
a = initial concentration 
(Remington's 1985.) 
1.2.1.2.Physical Stability :- 
                 Physical changes may result in diminished bioavailability and efficacy or 
may adversely affect other properties such as dispersability, acceptability to the 
patient and convenience for use. 
1.2.1.2.1.Types of physical changes:- 
1.2.1.2.1.1.Volatility of constituents :- 
        Drugs, solvents and excipients with high vapor pressure can be lost from 
medicinal products during manufacture and storage .Such drugs should be kept 
in well-closed airtight containers to avoid loss of active constituents, also the 
degradation product in tablet may sublime and appear as a deposit on tablet 
surface or in the walls of the container (asprin → saliciylic acid) . Also volatility 
of solvents in solutions lead to potentially hazardous concentrations of 
preparations especially in poorly closed, partially- filled containers kept in a 
warm dry place. Also loss of water by evaporation from aqueous solutions in 
warm dry conditions may result in crystallization of the drug or excipients; 
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similarly creams may lose water and form thick layer on the surface; the 
emulsion may crack.  
1.2.1.2.1.2.Changes in the water content of solids:- 
          Water can be sorbed on many solid drugs, exipients and medicinal 
products. In many substances water is bound rather than unbound. Bound water 
interacts physically with solids and its equilibrium vapor pressure is less than 
that of unbound water; bound water may be entrapped in pores or may be 
molecularly bound to form crystalline hydrates. 
           Many materials are hygroscopic (for example glycerol), that they gain (or 
loss) water in accordance with relative humidity; some are deliquescent that is 
they take up water and dissolve. Some salts (for example sodium sulphate) are 
efflorescent, their tendency to loss water to form lower hydrate or the anhydrous 
salt depend on relative humidity and temperature. 
Storage of hard gelatin capsules at high relative humidity may result in the 
capsules becoming sticky and distorted.In very dry conditions water is desorbed 
from the capsules shells, causing shrinking. 
      In filled capsules , moisture may be transferred from the shell to its contents; 
if drug or excipients, are hygroscopic which could lead to chemical degradation , 
formation of hydrates ,or the production of a hard cement –like mass from which 
the drug would be slowly  released after administration which lead to reduced 
bioavailability . 
       Soft gelatin capsules are specially sensitive to conditions of relative 
humidity greater than 60% since irreversible softening may occur, and they may 
become tacky and bloated. 
 - 19  - 
 
           The uptake or loss of water from solid dosage forms can result in 
undesirable changes in properties such as hardness, disintegration time, 
dissolution rate, bioavailability and efficacy. 
           Dry powders and granules may become aggregated to form a cake.     
 (Walter Lund 12 edition) 
1.2.1.2.1.3.Sorption :- 
         Change in crystal form, habit, and size of solid can affect not only the 
physical properties of medicine but also its bioavailability. 
1.2.1.2.1.4.Crystal form :- 
          Some drugs can exist in several crystal forms or polymorphs, which 
represent different arrangements of molecules with in the crystal lattice; although 
chemically identical polymorphs differ in physical properties because of 
differences in free energy. 
         At a given temperature and in a particular solvent, only one form is 
thermodynamically stable; other metastable forms tend to be converted to the 
stable form.  
        Metastable forms have a higher free energies, higher solubilities and 
dissolution rates and lower melting points than have the thermodynamically 
stable forms. 
        Conversion of a metastable form to the stable form of drug usually occurs 
more rapidly in suspension rather than in solid dosage forms and is often 
associated with crystal growth, which may lead to caking of the suspended 
particles. 
         Large fluctuations in storage temperatures should be avoided to minimize 
change in crystal form of a drug.   
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         Polymorphic changes can also occur during mechanical treatment of solid 
drugs. 
1.2.1.2.1.5.Crystal habit :- 
         Some crystal forms of substances may exist in different habits or external 
shapes; examples are prismatic, tabular, and isometric habits of an orthorhombic 
crystal form. Change in habit in a suspension can affect physical properties such 
as dissolution rate and the ability to flow through a syringe needle. 
         Large fluctuations in storage temperatures should be avoided to minimize 
change in crystal habit.  . 
1.2.1.2.1.6.Crystal growth :- 
        Crystals of a drug may grow in suspension because of temperatures 
fluctuation; dissolution of small crystals occurs when the temperature is raised 
followed by deposition into large crystals during cooling. Even at constant 
temperature crystal growth may occur in suspensions of drugs such as 
corticosteroids that contain very small particles, because such tiny crystals have a 
higher solubility in water but deposit on the larger crystals. 
Crystal growth can be minimized by:- 
Addition of surfactant or polymers. 
Use a narrow size range of particles. 
Increasing the viscosity of vehicle. 
 Avoiding large fluctuations in storage temperatures.    
(Walter Lund 12 edition page 296) 
1.2.1.2.1.7.Crystallization from solution :- 
             Crystals of a drug may be deposited from solutions because of a fall in 
temperature or change in pH in supersaturated solutions. 
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1.2.1.2.1.8 Precipitation in Galenicals :- 
        Inert matter derived from the contents of plant cells may coagulate in galenicals 
such as liquid extracts (tinctures); this precipitate is often known as ،pitching ،.  
1.2.1.2.1.9.Physical change in Emulsions :- 
        The physical instability of emulsions occurs in three main forms: flocculation 
where the interfacial film is not broken; 
 (1) Cracking: - Where the globules coalesce because of rupture of the interfacial 
film. 
(2) Creaming: - Where the globules move towards the surface of the product 
(emulsions).  
(3) Sedimentation: - Where the movement of globules is down wards. 
These changes are often accompanied by change in viscosity of the emulsion. 
1.2.1.2.1.10.Physical change in suspensions :- 
          The physical rate change of a solid drug in suspension or in a liquid depends 
largely on the magnitude of the opposing forces of attraction and repulsion. 
Attraction between particles occurs because of relatively week London-van der 
Waal´s forces whereas repulsion is caused by electrical double layer that surrounds 
each particle. If the forces of repulsion are greater than those of attraction, the 
suspension is deflocculated, that is, each particle settles slowly and individually to 
form sediment; sometimes the particles may aggregate to form an indispensable 
cake. In contrast if the attractive forces predominate, the particles come together to 
form loose floccules that settle rapidly to produce a readily dispersed sediment; the 
suspension is said to be flocculated. 
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1.2.1.2.1.11.Other physical changes :- 
Semisolids: - Ointments, creams and pastes may soften, harden, or become granular 
or gritty during storage Suppositories and pessaries may soften ,harden, or shrivel.  
Uncoated tablets:- Tablets may crumble or break during packaging or transport 
,crack or chips may be evident in tablet surfaces . Change in hardness, disintegration 
rate, or dissolution rate may occur. A moltteled appearance in coloured tablets may 
be caused during manufacture by intragranular migration of dye during wet 
granulation.  
Coated tablets:-During manufacturer clumping of film coated tablets may occur 
where inadequate drying of the coat results in tacky tablets that stick to neighboring 
tablets.  
1. 2.1.3 Microbiological stability :- 
          Many liquid medicines can support the growth of micro –organisms. Aqueous 
preparations such as solutions, suspensions, and oil in water in emulsions are 
especially susceptible to microbial growth .Growth may also occur in tablets and 
other solid dosage forms that contain some water . 
          Contamination of products with bacteria, moulds or yeasts may occur during 
manufacture, dispensing, storage, or use and may be derived from water and from 
drug substances or excipients ;other sources include packaging materials, premises, 
equipment, clothing, workers, and the atmosphere. 
            Proliferation of micro –organisms in medicinal products is unacceptable for 
the following reasons:- 
The presence of pathogenic bacteria, moulds, yeasts, or endotoxines can be 
hazardous to the patient particularly in solutions or emulsions administered 
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by intravenous infusion or solutions introduced into the anterior chamber of 
the eye during surgical procedure.  
(2) Contamination with non pathogenic micro organisms can result in spoilage of 
the product. 
 (Walter Lund 12 edition ) 
1.3. Storage and Distribution of  pharmaceutical products:- 
       The quality of a pharmaceutical product can be affected by a lack of adequate 
control over numerous activities which occur during the distribution process. 
Furthermore the distribution process has generally not been well-emphasized with 
regard to the need for establishment, development, maintenance and control over the 
activities involved. . In order to maintain the original quality every activity in the 
distribution of pharmaceutical products should be carried out according to the 
principles of good manufacturing practice (GMP), good storage practice (GSP) and 
good distribution practice (GDP). 
 1.3. 1 Distribution 
        The division and movement of pharmaceutical products from the premises of 
the manufacturer of such products, or another central point, to the end user thereof, 
or to an intermediate point by means of various transport methods, via various 
storage and/or health establishments. 
1.3.3.2.Good distribution practices (GDP) (new):- 
       Good Distribution Practices are that part of quality assurance that ensure that 
the quality of a pharmaceutical product is maintained through adequate control 
throughout the numerous activities which occur during the distribution process.  
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1.3.3.3. VEHICLES AND EQUIPMENT:-  
? Vehicles and equipment used to distribute, store, or handle pharmaceutical 
products should be suitable for their use and appropriately protective of the 
products to prevent exposure to conditions that could affect their stability 
and packaging integrity, and prevent contamination of any kind.  
? The design and use of vehicles and equipment must aim to minimize the 
risk of errors and permit effective cleaning and/or maintenance, in order to 
avoid contamination, build-up of dust or dirt and/or any adverse effect on 
the quality of pharmaceutical products being distributed.  
? Dedicated vehicles and equipment should be used, where possible, when 
handling pharmaceutical products.  
? Where non-dedicated vehicles and equipment are used, procedures must 
be in place to ensure that the quality of the pharmaceutical products will 
not be negatively influenced.  
? Appropriate cleaning should be performed, checked and recorded 
? Defective vehicles and equipment should not be used, and should either be 
removed or labeled as such.  
? There should be procedures in place for the operation and maintenance of 
all vehicles and equipment involved in the distribution process, including 
cleaning and safety precautions.  
? Vehicles, containers and equipment should be kept clean and dry and free 
from accumulated waste. A written cleaning programmed should be 
available, indicating the frequency of cleaning and the methods to be used.  
? Vehicles, containers and equipment should be kept free from rodents, 
vermin, birds and other pests. There should also be written programmed 
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for such pest control. Cleaning and fumigation agents should not have an 
adverse effect on product quality.  
? Equipment used for the cleaning of vehicles should be chosen and used so 
as not to constitute a source of contamination.  
? Special attention should be given to the design, use, cleaning and 
maintenance of all equipment used for the handling of pharmaceutical 
products which are not in a protective shipping carton or case.  
? Where special storage conditions (e.g. temperature and/or relative 
humidity), different from or limiting the expected environmental 
conditions, are required during transit these should be provided, checked, 
monitored and recorded. All monitoring records should be kept for a 
minimum of the shelf-life of the product distributed plus one year, or as 
required by national legislation. Recorded monitoring data should be 
reviewed on receipt of pharmaceutical products to assess whether required 
storage conditions have been met.  
? Equipment used for monitoring conditions within vehicles and containers, 
e.g. temperature and humidity, should be calibrated.  
? Vehicles and containers should be of sufficient capacity to allow orderly 
storage of the various categories of pharmaceutical products during 
transportation.  
? Where possible mechanisms should be available to allow for the 
segregation during transit of rejected, recalled and returned pharmaceutical 
products as well as suspected to be counterfeits. Such goods must be 
securely packaged, clearly labeled, and be accompanied by appropriate 
supporting documentation.  
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? Measures should be in place to prevent unauthorized persons from 
entering and/or tampering with vehicles and/or equipment, as well as to 
prevent the theft or misappropriation thereof.  
.(WHO Working document QAS/04.068/Rev.2) 
1.3.2. Storage:-      
 The storing of pharmaceutical product up to the point of use under specified 
condition of temperature and relative humidity.  
1.3.2.1. Premises, Warehousing, and Storage:- 
     Good storage practice (GSP) is applicable in all circumstances where 
pharmaceutical products are stored throughout the distribution process. 
1.3.2.2. Storage areas:- 
? Precautions must be taken to prevent unauthorized persons from entering 
storage areas.  
     Storage areas should be of sufficient capacity to allow the orderly storage of 
the various categories products, namely bulk and finished products, products 
in quarantine, and released, rejected, returned or recalled products.  
? Storage areas should be designed or adapted to ensure good storage 
conditions. In particular, they should be clean and dry and maintained within 
acceptable temperature limits.Where special storage conditions are required 
on the label (e.g. temperature, relative humidity), these should be provided, 
checked, monitored and recorded. Pharmaceutical products should be stored 
off the floor and suitably spaced to permit cleaning and inspection. Pallets 
should be kept in a good state of cleanliness and repair.  
? Storage areas should be clean, and free from accumulated waste and 
vermin. A written sanitation program should be available indicating the 
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frequency of cleaning and the methods to be used to clean the premises and 
storage areas.  
There should also be a written program for pest control. The pest-control 
agents used should be safe, and there should be no risk of contamination of 
the materials and pharmaceutical products. There should be appropriate 
procedures for the clean up of any spillage to ensure complete removal of any 
risk of contamination.  
? Receiving and dispatch bays should protect products from the weather. 
Reception areas should be designed and equipped to allow containers of 
incoming pharmaceutical products to be cleaned, if necessary, before storage.  
? Where quarantine status is ensured by storage in separate areas, these 
areas must be clearly marked and their access restricted to authorized 
personnel. Any system replacing physical quarantine should provide 
equivalent security. For example, computerized systems can be used, 
provided that they are validated to demonstrate security of access.  
? If sampling is performed in the storage area, it should be conducted in 
such a way as to prevent contamination or cross-contamination. Adequate 
cleaning procedures should be in place for the sampling areas.  
? Physical or other equivalent validated (e.g. electronic) segregation should 
be provided for the storage of rejected, expired, recalled or returned products. 
The products, and areas concerned should be appropriately identified.  
? Radioactive materials, narcotics and other hazardous, sensitive and/or 
dangerous pharmaceutical products, as well as products presenting special 
risks of abuse, fire or explosion, (e.g. combustible liquids and solids and 
pressurized gases) should be stored in a dedicated area that is subject to 
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appropriate additional safety and security measures. Pharmaceutical products 
should be handled and distributed according to good manufacturing practice. 
? Pharmaceutical products should be handled and stored in such a manner 
as to prevent contamination, mix-ups and cross-contamination. 
? A system should be in place to ensure that pharmaceutical products due to 
expire first are sold and/or distributed first (FEFO). Where no expiry dates 
exist for the products, the FIFO principle should be applied. 
? Broken or damaged items should be withdrawn from usable stock and 
separated.  
       Storage areas should provide adequate lighting to enable all operations to 
be carried out accurately and safely.  
1.3.2.3.Storage cconditions :- 
                 Storage conditions for pharmaceutical products should be in compliance 
with the labeling, which is based on the results of stability testing.  
1.3.2.4.Monitoring of storage conditions  
                Recorded temperature monitoring data should be available for review. The 
equipment used for monitoring should be checked at suitable predetermined 
intervals and the results of such checks should be recorded and retained. All 
monitoring records should be kept for at least the shelf-life of the stored material or 
product plus one year, or as required by national legislation. Temperature mapping 
should show uniformity of the temperature across the storage facility. It is 
recommended that temperature monitors be located in areas that are most likely to 
show fluctuations.  
       Equipment used for monitoring should also be calibrated at defined intervals.  
.(WHO Working document QAS/04.068/Rev.2) 
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1.3.3.2.4. Labeled storage conditions:- 
       The following table shows the meaning of storage conditions defined in the 
label of the drug :- 
Table (1) storage conditions defined in the label of the drugs in general:- 
On the label Means 
Do not store over 30 C˚ From +2 C˚ to + C˚30 
Do not store over 25 C˚ From +2 C˚ to +25 C˚ 
Do not store over 15 C˚ From +2 C˚ to +15 C˚ 
Do not store over 8 C˚ From +2 C˚ to +8 C˚ 
Do not store below 8 C˚ From +8 C˚ to +25 C˚ 
Protect from moisture No more than 60% RH in normal 
storage condition; to be provided to 
the patient in moisture resistant 
container. 
Protect from light to be provided to the patient in light 
resistant container. 
  
 (WHO, Quality assurance of pharmaceuticals a compendium guidelines and related 
materials) 
1.3.3.2.5. The actual storage conditions in Khartoum :- 
     The prevalent storage and handling facilities of the medicinal products within 
Khartoum province was investigated and inspected with regard to compliance with 
requirement  of  good storage practice (GSP) and good distribution practice (GDP)    
    The  following results were obtained:-   
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1.3.3.2.6Available medicine storage facilities:- 
25% are normal stores.  
20% are normal stores with domestic refrigerators. 
20% are normal stores with specially designed refrigerators for medicines storage. 
10%are domestic refrigerators. 
5%are cold room with domestic refrigerators. 
5% are cold room with normal stores with domestic refrigerators. 
5% are normal stores with domestic refrigerators and specially designed 
refrigerators for medicines storage. 
    1.3.3.2.7. Location of store:- 
30%Industerial area. 
10%Residential area. 
40%Puplic market area. 
20%Hospitals. 
1.3.3.2.8 Transportation facilities:- 
            35%Special container with ice bag and refrigerated vehicles. 
            55%No facilities. 
            5% Special container with ice bag and no facilities. 
            5%Non refrigerated vehicles. 
 1.3.3.2.9.Electricity availability:-  
30%very good. 
55%good. 
15%poor. 
 1.3.3.2.10. Temperature control:- 
30%very good (controlled and monitored). 
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40%good (controlled and no monitoring). 
30%poor (no monitor and no control) 
(Hussein A. H. august 2006) 
1.4.Good manufacturing practices (GMP )  
It is the part of quality assurance which ensures that products are consistently 
produced and controlled to the quality standards appropriate to their intended use 
and as required by the marketing authorization. 
 .(WHO Working document QAS/04.068/Rev.2) 
1.5. Climatologically Normals For the period (1971-2000):- 
          The metrological authority is the main body which is responsible for detecting 
the temperatures and relative humidity in different areas of Sudan; they calculate the 
mean temperature and relative humidity for each month by taking the average of 30 
years. The following tables show the average of temperatures and relative humidity 
for some selected areas in Sudan:- 
 
 
 
 
  
  Table NO. ( 2) Expected  
temperature over a year  in   
Khartoum :-          
    Sudan :- 
                                                                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table NO. ( 3)  Expected 
temperature over a year  in Port 
Sudan:-   
 
 
 
 
 
 
 
 
Month 
Mean 
Temperature 
C˚ 
 
RH% 
Max Min 
January 26.6 19.4 65 
February 26.9 18.7 65 
March 28.5 19.5 63 
April 31.8 21.7 59 
May 35.4 24.2 53 
June 38.4 26.3 44 
July 40.7 28.5 44 
August 40.4 29.0 46 
September 37.9 27.1 55 
October 33.8 25.3 67 
November 30.9 23.7 69 
December 28.3 21.1 68 
Annual 33.3 23.7 53 
 
 
Month 
Mean 
Temperature 
C˚ 
 
RH% 
 Max Min 
January 30.7 15.6 26 
February 32.6 16.8 21 
March 36.5 20.3 16 
April 40.4 24.1 15 
May 41.9 27.3 20 
June 41.3 27.6 26 
July 38.5 26.2 42 
August 37.6 25.6 48 
September 38.7 26.3 41 
October 39.3 25.9 29 
November 35.2 21.0 26 
December 31.7 17.0 29 
Annual 37.0 22.8 28 
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Table NO. (4) Expected 
temperature over a year in 
Dongola:- 
 
 
 
 
Table NO. (5) Expected 
temperature over a year in 
Elgadarif:- 
 
 
 
Month 
Mean 
Temperature 
C˚ 
 
RH% 
 Max Min 
January 26.5 8.7 35 
February 29.3 10.1 29 
March 33.7 14.0 23 
April 38.9 18.9 19 
May 42.2 23.2 17 
June 43.1 24.9 17 
July 42.6 25.5 20 
August 42.2 25.7 21 
September 41.8 25.4 21 
October 39.0 21.8 23 
November 32.1 14.9 30 
December 28.2 10.3 35 
Annual 36.6 18.6 24 
 
 
Month 
Mean 
Temperature 
C˚ 
 
RH%
 Max Min 
January 34.9 17.2 34 
February 36.6 18.3 27 
March 39.3 21.4 23 
April 41.4 24.2 23 
May 40.6 25.4 34 
June 37.8 23.5 48 
July 33.6 21.7 65 
August 32.5 21.3 72 
September 34.4 21.6 66 
October 36.9 22.3 49 
November 37.4 21.2 33 
December 35.6 18.4 35 
Annual 36.7 21.4 42 
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Table NO. (6) Expected temperature over a year  in Elfashir :- 
 
 
 
Month 
Mean 
Temperature 
C˚ 
 
RH% 
 Max Min 
January 29.7 13.1 23 
February 32.0 15.2 19 
March 35.6 18.8 15 
April 38.8 12.7 15 
May 39.4 24.5 28 
June 37.7 24.2 40 
July 34.2 22.8 61 
August 33.3 22.3 67 
September 35.2 22.4 59 
October 36.8 22.4 37 
November 30.6 18.0 25 
December 30.4 14.2 26 
Annual 34.7 20.0 35 
 
(Metrological authority data sheet 2006) 
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1.6. Global worming:-                                                                                      
Global Warming is defined as the increase of the average temperature on 
Earth. As the Earth is getting hotter, disasters like hurricanes, droughts 
and floods are getting more frequent.                                                                        
Over the last 100 years, the average temperature of the air near the 
Earth's surface has risen a little less than 1° Celsius (0.74 ± 0.18°C, or 1.3 
± 0.32° Fahrenheit). The data show that an increase of one degree Celsius 
makes the Earth warmer now than it has been for at least a thousand 
years. Out of the 20 warmest years on record, 19 have occurred since 
1980. The three hottest years ever observed have all occurred in the last 
eight years; this phenomenon make us aware to take care about the 
storage conditions especially that Sudan lie in the area which has great 
changes in temperatures as show in figure (1).  
Figure (1) Map for temperature changes due to global warming:- 
 
 
Karin Lindinger, Allianz. Com publishing date: April 30, 2007 
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1.7. Effect of transportation:-  
           The effect of transportation was already studied using ergometrin, 
as general feature, of all the pharmaceutical products investigated, no 
significant degradation was experienced as a result of transportation 
from Europe to port Sudan. However, a significant decrease in the 
content occurred immediately after dispatch of samples to Khartoum 
medical stores, whereupon the content dropped to a value of 89.5%, 
which is below the USP lower limit.  
(I.O.AbuReid  etal., 1990.) 
    1.8.The targeted drug:- 
1.8.1.Dexamethasone:- 
 Dexamethasone is a synthetic glucocorticoid and an isomer of 
betamethasone. It is a white crystalline powder with melting point 268 C 
˚ to 271 C˚, with decomposition. A solution in dioxan is dextrorotatory. 
1.8.1.1. Structure :- 
C22H29FO5 ----- 392.41  
HO
HO OH
H
H
H
H
O
O
F
H3C
H3C CH3
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1.8.1.1. Structure activity relation ship:- 
? The OH group at position 17 is very important for anti-
inflammatory activity. 
? The fluoride in position 9 increase the anti-inflammatory effect. 
? The methyl group at position 16 decrease the side effect. 
       1.8.1.2. Solubility:- 
          Practically insoluble in water; soluble 1in 42 of ethanol 
and1in165of chloroform; soluble in acetone; sparingly soluble in 
methanol; very soluble in ether. 
(Clark´s analysis of drugs and poisons) 
1.8.2. Dexamethasone sodium phosphate :- 
    1.11.2.1 Structure:- 
C22H28FNa2O8P ----- 516.41 
HO
HO O
H
H
H
H
O
O
F
H3C
H3C CH3
p
O
ONa
ONa
 
melting point 233 C ˚ to 235 C˚ 
    1.11.2.2. Solubility :- 
         Soluble 1in2 of water; sparingly soluble in dehydrated alcohol; 
practically in soluble in chloroform and ether. 
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(Walter Lund 12 edition) 
1.9. Stability of dexamethasone  
           Dexamethasone sodium phosphate injection should be 
protected from light and dexamethasone tablets should be stored in 
well-closed containers protected from light.  
(Walter Lund 12 edition) 
               The stability of dexamethasone has been well studied:- 
Sterile dexamethasone acetate suspensions and dexamethasone sodium 
phosphate injections that had been stored in hospital pharmacies across 
the United States was studied. Through a voluntary FDA drug stability 
program, all hospital pharmacies in the United States were asked in 
October 1981 to complete a response card indicating information about 
the sterile dexamethasone acetate suspensions and dexamethasone 
sodium phosphate injections they had in stock. Based on the responses, 
FDA selected 21 samples of sterile dexamethasone acetate suspensions 
(representing two manufacturers) and 114 samples of dexamethasone 
sodium phosphate injection (representing 11 manufacturers). These 
samples were analyzed for identification, pH, and strength. All samples 
of sterile dexamethasone acetate suspension met USP requirements. 
Eleven samples of dexamethasone sodium phosphate injection 
representing 10 lots from three manufacturers failed USP assay 
requirements for strength. All samples that failed to meet strength 
requirements showed evidence of degradation by oxidation. Sterile 
dexamethasone acetate suspensions appear to be stable when stored 
under actual marketplace conditions, but there is a problem with the 
shelf-life stability of dexamethasone sodium phosphate injections made 
by some manufacturers.  (Coffman HD,etal. , 1983 Volume  40) 
 - 61  - 
 
                A commercial sample of dexamethasone sodium phosphate 
solution for injection was found to contain 56% of the labeled 
concentration and to be extensively contaminated with a white insoluble 
solid, which was identified as a mixture of the 16α- and 16β-methyl 
epimers of 9-fluoro-11β-hydroxy-16methylandrosta-1,4-Diene-
3,17Dione after examination by high performance liquid 
chromatography ,TLC,UV, and IR spectrophotometry. 
(Eric C.Juenge and James F.Brower  1979) 
            Dexamethasone tablets was assayed by direct ultraviolet 
absorption at 240 nm as well as colorimetrically following the official 
method .The tablets were similarly treated ; the direct 
spectrophotometric determination for a methanolic extract gave 
higher result than the colorimetric method, this is due to the 
decomposition product which absorbs at that wave length , This 
decomposition product was separated using TLC methods. 
(S.K. Wahba, etal., July1968) 
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Aim of 
The Research 
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      1- Depending on the reported stability studies of dexamethasone and 
dexamethasone sodium phosphate it was thought of great interest and 
importance to check the stability of formulations of dexamethasone and 
dexamethasone sodium phosphate available in Sudan.  
       
2- The study is aimed to cover the effect of actual storage conditions on 
the formulations available in pharmacies and drug stores in different 
areas in Sudan. 
    
3- The outcome of point (1)and (2) are :  
(A)  To find out the suitable storage conditions for such life saving drugs.  
(B)  Make authorities appreciate importance of such stability studies.    
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Chapter 3 
Experimental 
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3.1.Instrumentation:- 
3.1.1 Four decimal sensitive balance (ADAMS) was used for weighing 
all materials. 
3.1.2 Double beam UV-VIS spectrophotometer 1700 Shimadzu 
Pharmaspec , was used for quantitative analysis of dissolution of 
dexamethasone tablets. The spectral width was ( 2 nm) and the 
wavelength scanning speed was medium . The absorption spectra of test 
and reference solutions were recorded in 1 Cm quartz cells at the wave 
length  240 nm  . 
3.1.3. Two High performance liquid chromatography were used:- 
3.1.3.1. Knauer which was connected to UV/VIS detector ( K-
2600),HPLC pump K-1001 ,and brackets injector valve with 25µL 
sample loop  and laboratory computing integrator . 
3.1.3.2. Shimadzu which was connected to UV/VIS detector ( SPD-
10AVP) ,            with Shimadzu auto sampler injector(SIL -10ADVP) 
,Shimadzu (SCL-10 AVP)system controller ,Shimadzu liquid 
chromatograph (LC-10 AT VP)and Shimadzu degasser(DG-14A) . 
3.1.4.The separations were performed on Thermo column packed with 
octadeceyl -silane chemically bonded to silica  250*4.6 mm  at room 
temperatures . 
3.1.5. ERWEKA DT6 dissolution tester (apparatus1). 
3.1.5. Steam bath. 
3.1.6. FN400 Oven. 
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3.1.7.Power sonic 405 (Micro process controlled Bench-top ultrasonic 
cleaner). 
3.1.8. Jenway 3510 pH meter. 
 
3.2.Materials 
 
3.2.1. Formulations selected to be analyzed:- 
3.2.1.1 Dexamethasone sodium phosphate. Injection 4mg/ml :- 
2.1.1. Manufacturer:-Shanghai pharmaceutical co., LTD. 
2.1.2. Batch number :-  070408. 
2.1.3. Manufacture date :-04/2007. 
2.1.4. Expiry date:-04/2010. 
2.2. Dexamethasone tablet 1.5mg/tablet :- 
2.2.1. Manufacturer:-Organon and Medico labs 
2.2.2. Batch number:-  152365 (Organon) and 246 (medico). 
2.2.3. Manufacture date :-    _(Organon) and11/2007 (medico). 
2.2.4. Expiry date:- 09/2009(Organon) and11/2010 (medico).  
2.3. Dexamethasone sodium phosphate eye ointment 0.05% :  
2.3.1. Manufacturer :-Alcon cusi 
2.3.2. Batch number :- 5CTB1A. 
2.3.3. Manufacture date :- 12/2005. 
2.3.4. Expiry date:- 12/2010. 
2.4. Dexamethasone oral solution10mg/100ml:-  
2.4.1. Manufacturer:- The Arab Drug company. 
2.4.2. Batch number:- 730222. 
2.4.3. Manufacture date:- 6/2007. 
2.4.4. Expiry date:- 6/2010. 
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   3.3. Study design and sampling :-                                                 
               Each dosage form was represented by certain drug which is stable in 
normal controlled room temperature and humidity but when it is exposed 
to drastic conditions it may show changes due to instability . To exclude 
the effect of the drug as one factor  the same drug in different dosage 
forms were selected. Dexamethasone was chosen in this work for tablets, 
ointments ,syrups and dexamethasone sodium phosphate for injections.  
Samples were collected directly from manufacturer and the central  
medicine stores (C M S ) ; samples were analyzed first as zero time , then 
at different time intervals according to the following protocol :- 
1-One batch of each drug formulation was stored in stability cabinet  
at temperature of 30 ºC and 70% R H (Registration requirement). 
2- Part of the same batch stored in the cabinet was distributed to 
different areas in Sudan ; these areas (Dongola, Port Sudan,  Elfashir 
,Elgadarif and Khartoum ) were selected to cover the different 
climatic conditions in Sudan . The distribution took place by 
controlled temperature vehicles and stored in these areas at actual 
storage conditions in retail pharmacies, and they were collected at the 
time of  test and send by plane or controlled temperature vehicles  as 
follows:- 
• after 4 month 
• after 8 month  
• after 12 month and so on till the samples show 
significant changes during the shelf life. 
The same batches were stored in well controlled conditions as 
controls. 
3.4.Analysis of samples: 
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            Samples were analyzed according to the USP HPLC methods to 
assess the affect of the real storage conditions on stability of the different 
dosage forms.  
             All methods used were USP 2007 except for the dissolution test 
for the dexamethasone tablets that because one of the reagents needed for 
the test was not available (tetrazolium blue). 
3.4.1.Reagents :- 
 
3.4. 1.1. Samples and standard preparations :- 
                 All reagents used for sample and standard preparations were of 
analytical grade obtained from different sources as follows:- 
Table  (7) reagents used for samples and standards preparation 
No Reagent Source 
1 Methanol Romil pure chemistry 
2 Acetonitrile Romil pure chemistry 
3 Anhydrous acetic acid Scharlue 
4 Chloroform BDH laboratories 
supplier 
5 Hydrochloric acid 37% BDH laboratories 
supplier 
6 Alcohol Romil pure chemistry 
7 Monobasic Potassium 
phosphate 
Loba chemie 
8 Monobasic sodium phosphate Loba chemie 
9 glacial acetic acid Scharlue 
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3.4.1.2 For dexamethasone sodium phosphate injection:- 
                For sample and standard preparation suitable degassed solution 
of 0.01M monobasic potassium phosphate in a mixture of methanol: 
water (1:1) was used to dilute the injection to the specified concentration. 
3.4.1.3. For dexamethasone tablets :- 
               For sample and standard preparation dilute methanol (1 in 2) in 
water was used. 
3.4.1.4. For dexamethasone sodium phosphate eye ointment:- 
              For sample and standard preparation chloroform and alcohol- 
aqueous phosphate buffer were used. 
3.4.1.5. For dexamethasone oral solution:- 
           For sample and standard preparations a mixture of methanol and 
water (1:1) was used. 
3.4.1.2. Mobile phases preparations :- 
         Acetonitrile and methanol used for mobile phases preparations were 
of HPLC grade:-  
3.4.1.2. 1. For dexamethasone sodium phosphate injection:- 
            A filtered and degassed solution of 0.01M monobasic potassium 
phosphate in a mixture of methanol: water (1:1) was prepared. 
3.4.2. 2 for dexamethasone tablets:- 
            Filtered and degassed aqueous solution of acetonitrile (1 in 3) in 
water was used. 
3.4.2.3. for dexamethasone sodium phosphate eye ointment:-                                          
Filtered and degassed solution of methanol and 0.05M phosphate buffer  
(6.9 gram of monobasic sodium phosphate was dissolved in a liter of 
water) in a ratio of 52:48 was used. 
3.4.2.4 For dexamethasone oral solution:- 
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               A filtered and degassed mixture of methanol: water: glacial 
acetic acid (55:43:2) was used. 
 
 
3.4.1.3. Standard solutions preparations :- 
3.4.3.1. For  dexamethasone sodium phosphate injection assay:- 
An accurately measured weight of dexamethasone sodium phosphate 
standard (0.01gram) was dissolved in 100 ML diluting solution. 
3.4.3.2.For dexamethasone tablet assay:- 
An accurate weight of dexamethasone standard (0.01 gram) was 
transferred in to 100 ML volumetric flask, dissolved and dilute to volume 
with dilute methanol (1 methanol in 2 water). 
3.4.3.3   For dexamethasone sodium phosphate eye ointment assay:- 
An accurate weight of dexamethasone sodium phosphate standard 
(0.01gram) was transferred in to 100 ML volumetric flask, dissolved and 
dilute to volume with alcohol aqueous phosphate buffer, 5ML of this 
solution was transferred to 50ML volumetric flask and dilute to volume 
with alcohol with aqueous phosphate buffer. 
3.4.3.4 For dexamethasone oral solution assay:-  
An accurate weight of dexamethasone standard (0.01gram) was 
transferred in to 100 ML volumetric flask, dissolved and diluted with 
mixture of methanol: water (1:1), 5ML of this solution was transferred 
to10ML volumetric flask and diluted to volume with the same solvent. 
3.4.1.4.Sample preparation:- 
3.4..4.1. Dexamethasone sodium phosphate injection assay:- 
An accurately measured volume of injection (2ML) was diluted to 100 
ML with diluting solution. 
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3.4.4.2 Dexamethasone tablets:- 
3.4..4.2.1 Dissolution test:  
One tablet was introduced to each dissolution tester vessels which was 
filled with medium of 500 ml hydrochloric acid (37 %) 1 in 100 and 
basket (apparatus 1) was operated at 100 r.p.m. for 45 minutes at 37C˚. 
             (50 ml) of Filtered aliquot of dissolution media was extracted 
with three (15 ml) of chloroform, the combined extracts were evaporated 
on steam bath just to dryness, cooled and dissolved in (10 ml) of 
methanol.  
3.4.4.2.2. Dexamethasone tablets assay:- 
              10 tablets were accurately weighted, transferred to a mortar and 
finely powdered. A mass containing 5 mg of dexamethasone was 
accurately weighted and transferred in to50 ml volumetric flask, 
suspended in 30 ml of dilute methanol (1in2), sonicated for about 2 
minutes and shacked by mechanical means for 30 minutes , then diluted 
with the same solvent to volume . The solution was filtered through 
Whatman No 40 filter paper. 
3.4.4.3. Dexamethasone sodium phosphate ointment assay:- 
An accurate  weight of ointment (2.5 gram) was transferred to 100 ml 
beaker; 10ml of alcohol aqueous phosphate buffer was added and heated 
just to boiling and cooled .The contents of the beaker were transferred to 
separatory funnel containing 45ml of chloroform ;after shaking for one 
minute the upper layer was collected  in 25ml volumetric flask and the 
remaining  chloroform was extracted with two 5 ml of the buffer and the 
upper layer was collected in the same 25mlvolumetric flask , the volume  
was completed with same solvent and mixed . The solution was filtered 
through Whatman No 40 filter paper. 
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3.4.4.4. Dexamethasone oral solution:- 
             An accurately measured volume of oral solution was transferred 
into 50 ml volumetric flask and diluted to volume with mixture of 
methanol water (1:1). 
3.5. Procedures:- 
              3.5.1. For dexamethasone sodium phosphate injection :-  
An equal volumes (25µl) of samples and standard preparations were 
injected into the HPLC system at room temperature  connected with 
Thermo column 4.6mm *250mm with particle size 5µ packed with 
ODS(octadecyl silane chemically bonded to porous silica ) and equipped  
with UV detector capable of monitoring absorptions at 254 nm with flow 
rate  1.5 ml/minute ; the peak retention time was about 5 minutes. 
        3.5.2 Dexamethasone tablets:- 
3.5.2. 1.Dissolution test:- 
                The UV absorbance was recorded at 240 nm and 385  was used 
as value of (A ¹% 1 Cm) using methanol as a blank. 
3.5.2.2. Dexamethasone tablets assay:- 
                An equal volumes (25µl )of samples and standard preparations 
were injected in to HPLC at room temperature  connected with Thermo 
column 4.6mm *250mm with particle size 5µ packed with 
ODS(octadecyl silane chemically bonded to porous silica)  and equipped  
with UV detector capable of monitoring absorptions at (254 nm) with 
flow rate  2ML/minute, the peak retention time was 5 minutes. 
3.5.3. Dexamethasone sodium phosphate ointment assay:- 
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            An equal volumes (25µl) of samples and standard preparations 
were injected in to HPLC at room temperature  connected with Thermo 
column 3.9 mm *300mm backed with ODS(octadecyl silane chemically 
bonded to porous silica  and equipped  with UV detector capable of 
monitoring absorptions at 254 nm with flow rate  1.5ML/minute, the 
peak  retention time was 5 minutes. 
3.5.4. Dexamethasone oral solution assay:- 
                 An equal volumes (25µl) of samples and standard preparations 
were injected in to HPLC at room temperature  connected with Thermo 
column 4.6mm *250 Mm with particle size 5µ packed with 
ODS(octadecyl silane chemically bonded to porous silica)  and equipped  
with UV detector capable of monitoring absorptions at 254 nm with flow 
rate  2ml/minute, the peak retention time was 5 minutes. 
 
3.6.Validation of the non official methods(dissolution for tablets) :- 
As mentioned before the dissolution test of dexamethasone tablets was 
modified due to unavailability of tetrazolium blue, so we have to validate 
this modification. 
3.6.1. For dexamethasone tablet dissolution :- 
3.6.1.1. Linearity:- 
         The same procedure as in the dissolution was followed to prepare 
different solutions with concentrations of 15.0 , 10.0 , 6.0 , 3.0 , 1.5 µg 
/ML . The UV absorbance was recorded at (240 nm) and 385 was used 
as(A ¹% 1 Cm) and methanol as blank. 
3.6.1.2. Selectivity:- 
               Solutions of dexamethasone and prednisolone and clobetasone 
standards (which have structures very close to each other) were prepared 
in methanolic hydrochloric acid (1 in 100 ) and the ultraviolet spectrums 
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were recorded between 200 and 400 and methanolic hydrochloric acid 
was used as blank . 
 
 
3.6.1.3. Limit of quantitation :- 
             Concentrations of 15.0, 6.0, 3.0, 1.5 µg /ML of dexamethasone 
tablets were prepared from dissolution media after extraction and the 
ultraviolet absorbance was recorded at 240 nm and 385 was used as(A ¹% 1 
Cm) using methanol as blank. 
3.6.1.4. Sensitivity:-  
3.6.1.4.1. The ultraviolet absorbance:- 
              The UV absorbance of the dissolution media and dexamethasone 
standard prepared in methanolic hydrochloric acid was directly recorded 
at 240 nm. 
          The UV absorbance of the extracted dissolution media was 
recorded at (240 nm) and 385 was used as (A ¹% 1 Cm) and methanol as 
blank then compared with standard solution in methanol prepared in 
equivalent concentrations.  
          The UV absorbance of the dissolution media containing 
dexamethasone and dexamethasone standard prepared in methanolic 
hydrochloric acid was directly recorded at (254 nm).  
3.6.1.4.2. The HPLC method:- 
                    The dexamethasone standard and dissolution media of 
sample was prepared in concentrations of 3.0 µg /ml, 25 µl was directly 
injected in to HPLC system at room temperature connected with Thermo 
column 4.6mm *250mmwith particle size 5µ packed with ODS 
(octadecyl silane chemically bonded to porous silica )  and equipped with 
UV detector capable of monitoring absorptions at (254 nm) with flow 
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rate 2ml/minute, the beak appeared after 5 minutes when filtered and 
degassed aqueous solution of acetonitrile (1 in 3) was used as mobile 
phase. 
The extracted dissolution media and dexamethasone standard were 
prepared in concentrations of 3.0 µg/ml, 25 µl was directly injected in to 
HPLC at room temperature connected with Thermo column 4.6Mm 
*250Mm packed with ODS(octadecyl silane chemically bonded to 
porous silica )  and equipped with UV detector capable of monitoring 
absorptions at (254 nm) with flow rate 2ml/minute, the beak appeared 
after 5 minutes when filtered and degassed aqueous solution of 
acetonitrile (1 in 3) was used as mobile phase. 
3.6.1.5 Reproducibility:- 
                      The dissolution test was repeated three times in different 
days. 
3.6.1.6. Accuracy:- 
                  The dissolution test for samples was done and concentrations 
of 3.0 µg/ml (90%), 3.3µg /ml (100%) and 3.6. µg /ML (110%) were 
prepared then the UV absorbence compared with the theoretical one.   
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         The following tables and figures are obtained from analysis of 
different dosage forms of dexamethasone and dexamethasone phosphate 
marketed in Sudan using the analysis methods mentioned in chapter (3)  
4.1.Results for dexamethasone sodium phosphate injection assay: 
          The following equation was used to calculate the % content  of 
dexamethasone sodium phosphate injections assay :-  
% content dexamethasone sodium phosphate injection assay = 
AUC of sample * Concentration factor * potency of standard  /AUC of 
Standard 
 
Table 8: 
Follow up HPLC results of dexamethasone injections assay over year 
from Dongola, Elgadarif and Port Sudan: 
 
 
 Dongola RSD Elgadarif RSD Port- 
Sudan 
RSD 
Zero time 106.3% 
N=3 
0.012
7 
106.3% 
N=3 
0.012
7 
106.3% 
N=3 
0.0127 
4 month 98.8% 
N=3 
0.021
22 
105.2% 
N=3 
0.025
4 
105.3% 
N=3 
0.02262 
8 month 85.2% 
N=3 
0.028
04 
80.7% 
N=3 
0.023
03 
81.3% 
N=3 
0.00406 
12month 81.2% 
N=3 
0.026
2 
79.0% 
N=3 
0.021
2 
83.0% 
N=3 
0.02625 
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 Figure 4 Follow up HPLC results of dexamethasone injections assay 
over year from Dongola, Elgadarif and Port Sudan: 
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Table 9: Follow up HPLC results of dexamethasone injections assay 
from Elfashir, Khartoum and Stability cabinet:  
 
  
Elfashir 
RSD Khartoum RSD Stability 
 cabinet 
RSD C.D.S. 
Zero time 106.3% 
N=3 
0.0127 
 
106.3% 
N=3 
0.0127 106.3% 
N=3 
0.0127 106.3% 
N=3 
4 month 103.6 % 
N=3 
0.00990 99.4% 
N=3 
0.00525 96.9% 
N=3 
0 .0063    - 
8 month 84.8% 
N=3 
0.00133 84.03% 
N=3 
0.01773 90.3 0% 
N=3 
0.00096
 
- 
12month 84.6% 
N=3 
0.02265 79.3% 
N=3 
003336 86.8% 
N=3 
0.03888 103.1% 
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Figure 5 Follow up HPLC results of dexamethasone injections assay 
from Elfashir, Khartoum and Stability cabinet 
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Figure 6: Examples of HPLC chromatogram for dexamethasone 
sodium phosphate injection: 
? HPLC chromatogram for initial assay: 
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? HPLC chromatogram for assay after 8 month from Elgadarif 
and Dongola(concentration factor=1.61): 
 
 
 
Figure 7 : 
Comparison between assay results of dexamethasone sodium 
phosphate injections from different areas over 12month 
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Table 10: follow up results of dexamethasone sodium phosphate 
injections PH over a year : 
 Dongola Elgadarif Port- 
Sudan 
Elfashir Khartoum Stability 
 cabinet 
Zero time 7.80 7.80 7.80 7.80 7.80 7.80 
4 months 7.67 7.70 7.78 7.70 7.68 7.70 
8months 7.60 7.62 7.68 7.65 7.68 7.60 
12months 7.30 7.31 7.10 7.50 7.10 7.50 
 
Figure 8  
Comparison between PH results of dexamethasone sodium 
phosphate injections from different areas over 12month: 
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4.2.Results for dexamethasone tablets : 
          The following equation was used to calculate the % content  of 
dexamethasone tablets assay :-  
% content dexamethasone tablet = 
AUC of sample*Concentration factor*potency of standard /AUC of 
Standard 
Table 11 : Follow up Results of dexamethasone tablets 
(oradexone)assay from Elfashir, Khartoum and Stability cabinet: 
 Elfashir  
RSD 
Khartoum  
RSD 
Stability 
  cabinet 
RSD 
Zero time 99.8% 
N=3 
0.01629 99.8% 
N=3 
0.01629 99.8% 
N=3 
0.01629 
4 month 98.0% 
N=3 
0.017977 94.8% 
N=3 
0.0280 95.0% 
N=3 
0.006702 
8 month 92.3% 
N=3 
0.00533 94.3% 
N=3 
0.001731 94.4% 
N=3 
0.001737 
12 month 85.04% .001325 93.0% 
N=3
0.001967 89.6% 
N=3 
0.000407 
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Figure 9 Follow up Results of dexamethasone tablets (oradexone) 
assay from Elfashir, Khartoum and Stability cabinet: 
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N=3 
 Dongola RSD Elgadarif RSD Port- 
Sudan 
RSD 
Zero time 99.8% 
N=3 
0.01629 99.8% 
N=3 
0.01629 99.8% 
N=3 
0.01629 
4 moths 97.0% 
N=3 
0.01162 96.8% 
N=3 
0.005056 95.0% 
N=3 
0.01544 
8months 93.5% 0.006018 90.9% 
N=3 
0.019765 93.0% 
N=3 
0.02114 
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   Table 12: Follow up results of dexamethasone tablet (oradexone) 
assay from Dongola, Elgadarif and Port Sudan 
 
 
Figure 10. Follow up results of dexamethasone tablet (oradexone)  
assay from Dongola, Elgadarif and Port Sudan . 
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Table13 : Results of dexamethasone tablets assay from another 
company(Dexamed): 
 
 
 
 
N=3 
12months 90.8% 
N=3 
0.008166 90.2% 
N=3 
0.002563 86.8% 
N=3 
0.003156 
 Company 
store 
Pharmacy 
Zero time 104.2 104.2 
6 month 90.4 90. 3 
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Table14:Follow up results of dexamethasone tablets (oradexone) dissolution from 
 Dongola  
Zero time 101.2 98.3 98.5 97.4 104.7 97.4 
4 months 120.0 116.2 125.3 130.0 140.7 145.1 
8months 151.5 173.1 128.2 157.4 151.5 216.4 
Table15: Follow up results of dexamethasone tablets (oradexone) dissolution from  
Khartoum:- 
 
Table 16:.Follow up results of dexamethasone tablets (oradexone) dissolution 
 From Elfashir: 
 
 
Table17:Follow up results of dexamethasone tablets (oradexone) dissolution  
From Elgadarif :- 
 
   
 
Zero time 98.3 98.5 97.4 104.7 97.4 101.2 
4month 173.1 194.8 123.3 116.8 121.3 145.0 
8month 189.7 190.8 154.3 133.4 168.5 165.8 
ZEROTIME 98.3 98.5 97.4 104.7 97.4 101.2 
4 MONTH 163.9 171.4 172.6 152.5 166.2 133.5 
8MONTH 177.9 185.7 200.8 158.4 172.5 180.4 
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Table18:Follow up results of dexamethasone tablets (oradexone) dissolution  
From stability cabinet :- 
 
 
 
 
 
 
 
Table 19:Follow up 
results of 
dexamethasone tablet
(oradexone) dissolution from 
Port Sudan:- 
 
ZERO TIME 98.5 97.4 104.7 97.8 101.2 
4 MONTH 125.8 111.3 121.5 150.6 130.0 
8 MONTH 161.5 171.4 171.7 172.7 137.8 
 
 
 
ZERO TIME 101.2 98.3 98.5 97.4 104.7 97.4 
4 MONTH 160.2 185.4 140.3 100.1 115.0 125.6 
8MONTH 186.1 454.5 199.1 80.0 97.4 93.5 
ZEROTIME 98.3 98.5 97.4 104.7 97.4 101.2 
4 MONTH 138.5 116.8 168.8 123.8 121.2 129.8 
8MONTH 140.9 135.7 167.6 120.8 144.0 180.6 
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Figure 11.: Examples of HPLC chromatogram for dexamethasone 
tablet: 
? HPLC chromatogram for initial assay: 
 
 
? HPLC chromatogram for assay after 8 month from Khartoum  
?  
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Figure 12. :Comparison between dexamethasone tablets assay from 
different areas over 12month  
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4.3. For dexamethasone ointment: 
          The following equation was used to calculate the % content of 
dexamethasone ointments assay :-  
  
% content dexamethasone ointment = 
AUC of sample*Concentration factor/AUC of Standard 
Table 20 Follow up results for dexamethasone ointments assay from 
Elfashir, Khartoum and Stability cabinet : 
 
Figure13. Follow up results for dexamethasone ointments assay from 
Elfashir, Khartoum and Stability cabinet : 
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 Elfashir  
RSD 
Khartoum  
RSD 
Stability 
 cabinet 
RSD 
Zero time 110.6% 
N=3 
0.0151
78 
110.6% 
N=3 
0.0151
78 
110.6% 
N=3 
0.0151
78 
4 month 105.2 % 
N=3 
0.0162
2 
107.6% 
N=3 
0.0177
78 
110.0% 
N=3 
0.0229
1 
8 month 101.5% 
N=3 
0.0048
49 
107.5% 
N=3 
0.0098
34 
107.4% 
N=3 
0.0184
849 
12month 101.2% 
N=3 
0.0062
9 
105.1% 
N=3 
0.0023 104.5% 
N=3 
0.0087
1 
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Table 21:  
Follow up results of dexamethasone ointments assay from Port 
Sudan, Elgadarif and Dongola  
 Port 
Sudan 
 
RSD 
Elgadarif  
RSD 
Dongola RSD 
Zero time 110.6% 
N=3 
0.01517 110.6% 
N=3 
0.01517 110.6% 
N=3 
0.01517 
4 month 110.0% 
N=3 
0.02100
1 
109.1% 
N=3 
0.01712 109.3% 
N=3 
0.01590 
8 month 107.9% 
N=3 
0.01740 107.6% 
N=3 
0.00212 108.9% 
N=3 
0.01215 
12month 107.6 
N=3 
0.01274 98.16 
N=3 
0.02701 108.1 
N=3 
0.00983 
 
Figure 14 Follow up results of dexamethasone ointments assay from 
Port Sudan, Elgadarif and Dongola  
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Figure 4.12 : Examples of HPLC chromatogram for dexamethasone 
ointment 
? HPLC chromatogram for initial assay  
 
 
 
 
? HPLC chromatogram for assay after 8 month from cabinet 
and Alfashir : 
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Figure 16. :  
Comparison between assay results of dexamethasone ointments from 
different areas over 12month 
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4.4.For dexamethasone oral solutions : 
          The following equation was used to calculate the % content of 
dexamethasone oral solutions assay:-  
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% content dexamethasone oral solutions = 
AUC of sample*Concentration factor*potency of standard /AUC of 
Standard 
Table (22):   
Follow up results of dexamethasone oral solutions assay from 
Dongola, Elgadarif, Port Sudan and company store: 
 Dongola RSD Elgadarif RSD Port- 
Sudan 
RSD company 
store 
Zero time 100.2% 
N=3 
0.0084
11 
100.2% 
N=3 
0.00841
1 
100.2% 
N=3 
0.008411 100.2% 
4 months 89.8% 
N=3 
0.0163
01 
91.8% 
N=3 
0.00367
7 
92.5% 
N=3 
0.002658 - 
8months 76.4% 
N=3 
0.0282
33 
78.4% 
N=3 
0.00719
9 
77.9% 
N=3 
0.012921 - 
12months 64.4% 
N=3 
0.0268
22 
64.7% 
N=3 
0.00191 63.5% 
N=3 
0.01348 94.5% 
Figure17 Follow up results of dexamethasone oral solutions assay 
from Dongola, Elgadarif, Port Sudan and company store: 
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Table 23  Follow up results of dexamethasone oral solutions assay 
from Elfashir, Khartoum and Stability cabinet 
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 Elfashir RSD Khartoum RSD Stability 
 cabinet 
RSD 
Zero time 100.2% 
N=3 
0.008411 100.2% 
N=3 
0.008411 100% 
N=3 
0.008411 
4 month  87.9% 
N=3 
0.002085 94.2% 
N=3 
0.008764 94.9% 
N=3 
0.011407 
8 month 74.2% 
N=3 
0.035616 77.3% 
N=3 
0.010612 75.0% 
N=3 
0.0120 
12 month 65.6% 
N=3 
0.00241 62.98% 
N=3 
0.023339 65.1% 
N=3 
0.002921 
Figure18 Follow up results of dexamethasone oral solutions assay 
from Elfashir, Khartoum and Stability cabinet 
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Figure 19 : 
Comparison between assay results of dexamethasone oral solutions 
from different areas over 12month:  
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Figure 20: Examples of HPLC chromatogram for dexamethasone 
oral solution 
? HPLC chromatogram for initial assay  
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? HPLC chromatogram for  assay after 8 month from Khartoum 
  
 
 
 
 
 
Table24 : 
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Follow up results for dexamethasone oral solutions PH: 
 Dongola Elgadarif Port- 
Sudan 
Elfashir Khartoum Stability 
 cabinet 
Zero time 3.1 3.1 3.1 3.1 3.1 3.1 
4 months 2.97 2.92 2.97 2.95 2.99 2.97 
8 months 2.88 2.85 2.8 2.85 2.87 2.96 
12months 2.7 2.72 2.79 2.8 2.82 2.70 
 
Figure 21. 
Comparison between PH results of dexamethasone oral solutions 
from different areas over 12month 
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4.5. Results of  proposed method validations:- 
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4.5.1. Sensitivity:-  
Figure 22.HPLC chromatogram for dexamethasone tablets (zero 
time) added to dissolution media and directly injected to HPLC 
system at 240 nm 
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Figure23. 
HPLC chromatogram for dexamethasone tablets (zero time) added 
to dissolution media and injected to HPLC system at 240 nm after 
extraction process: 
 
 
 
 
 
 
Result of dexamethasone dissolution media injected to HPLC system 
after treatment =  95.8 % 
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Table 25                                                                                                     
show Comparison between ultraviolet absorbance of dexamethasone 
in dissolution media at 254 nm and 240 nm 
 
 
No 
Absorbance at 240 Absorbance at 254 
Standard sample Standard sample 
1 0.125 0.134 0.09 0.100 
2 0.127 0.137 0.09 0.098 
3 0.124 0.133 0.091 0.101 
average 0.125 0.134 0.090 0.099 
%content 107.7% 110.7% 
 
4.5.2. Linearity :- 
Table 26 show ultraviolet absorbance for different concentrations of 
dexamethasone tablets after dissolution treatment using extraction 
method 
 
concentration absorbance Content 
% 
15.0 µg/ml 0.630 109.0 
10.0 µg /ml 0.415 107.7 
6.0 µg /ml 0.255 110.3 
3.0 µg /ml 0.126 109.1 
1.5 µg /ml 0.07 121.2 
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Figure 24. show linearity of the ultraviolet absorbance method for 
dissolution using extraction method 
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Y=0.0415X+0.0044 
R² =0.9998 
 
4.5.3. Limit of quantitation :- 
Table No 27 show the absorbance of different concentrations of 
dexamethasone tablets after dissolution treatment using extraction 
method 
 
 
 
 
 
 
 
 
 
concentration absorbance 
15.0  µg/ml 0.630 
6.0 µg/ml 0.255 
3 .0µg/ml 0.126 
1.5 µg/ml 0.07 
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4.5.4. Accuracy:- 
 Table 28 Comparison between actual and theoretical results of 
Ultraviolet absorbance for different concentrations of 
dexamethasone tablets after dissolution treatment  
 
 
 
No 
Concentrations Theoretical Actual 
Absorbance Content% Absorbance Content% 
1 3.6 µg/ml 0.138 110% 0.134 108.6% 
2 3.3 µg/ml 0.127 100% 0.126 99.17% 
3 3.0 µg/ml 0.115 90% 0.111 87.3% 
 
4.5.5. Selectivity:- 
Table 29 Comparison between absorption wave length of 
dexamethasone, Prednisolone and clobetasone (have structural 
similarity) 
 
 
 
 
 
 
 
 
 
 
Sample  Absorbance wave 
length 
Absorbance 
dexamethasone 243.8 nm 0.522 
Prednisolone 247.8 nm 1.370 
clobetasone 238 nm 1.587 
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4.6. Order of Reaction 
4.6.1.Dexamethasone ointment : 
Table No 30 Result of dexamethasone ointment assay from stability 
cabinet 
 
Time/month Content% Log content % 
0 month 110.6 2.043 
4 month 110.0 2.041 
8 month 107.4 2.031 
12 month 104.5 2.019 
Figure25For zero order (plot content %against time/month) 
y = -0.5225x + 111.26
R2 = 0.9371
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Figure 4.5.5For first order: 
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4.6.2. Order of reaction for Dexamethasone injection 
Table No 31 results of Dexamethasone sodium phosphate injections 
From Dongola: 
Time/month Content% Log content % 
0 month 106.3 2.026 
4 month 98.8 1.99 
8 month 85.2 1.93 
12 month 81.2 1.90 
 
Figure4.6.2.For zero order(plot content %against time/month) 
y = -2.2225x + 106.21
R2 = 0.9625
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For first order(plot log content %against time/month) 
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4.6.3. Order of reaction for Dexamethasone tablets   
Table No 32.Result of dexamethasone (tablets) from Elfashir: 
 
Time/month Content% Log content % 
0 month 99.8 1.993 
4 month 98.0 1.991 
8 month 92.3 1.965 
12 month 85.0 1.929 
 
Figure 4.6.3.Order of reaction for dexamethasone tablets 
For zero order(plot content %against time/month) 
y = -1.2525x + 101.29
R2 = 0.9413
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For first order (plot log content %against time/month) 
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4.6.4. Order of reaction for Dexamethasone oral solution 
Table No 33 Result of dexamethasone Oral solutions from port 
Sudan: 
 
 
 
 
 
 
 
.Figure 4.6.4. For zero order (plot content %against time/month) 
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For first order (plot log content %against time/month) 
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Time/month %content Log 
content% 
Zero time 100.2 2.00 
4 month 92.5 1.96 
8month 77.9 1.89 
12 month 63.5 1.80 
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            Dexamethasone is a life saving drug used as a potent anti-
inflammatory and anti-allergic.In common with all glucocorticoid their 
suppressive action on the hypothalamic-pituitary-adrenal axis is greatest 
and most prolonged when they are given at night; This is the basis of the 
‘over night dexamethasone suppression test' for diagnosing Cushing's 
syndrome. Dexamethasone is also appropriate for conditions where water 
retention would be a disadvantage. A corticosteroid may be used in the 
management of raised intracranial pressure or cerebral edema that occurs 
as a result of malignancy.It was found in different dosage forms in Sudan 
(tablets, injections, oral solutions and ointments) which are stable in 
normal controlled room temperature but when they were exposed to 
drastic conditions they may show changes due to instability. (British 
national formulary 57) 
      Dexamethasone usually follows oxidation reaction as degradation path 
way. (Walter Lund 12 edition)   
       According to the USP zone classification Sudan was classified as zone 
iii (hot/dry) in which the measured temperature in open air is 24.4 ºC and 
39% R.H.  .The WHO classify Sudan as zoon iii and iv in which the 
measured temperature at open air is 26.4 ºC and the RH is 77%;  but the data 
obtained from the Metrological Authority show large fluctuations in 
temperatures during different seasons of the year and between day and night 
for  the same area;  for example:- 
            In Khartoum during January the temperature recorded at day is 
30.7 ºC and at night is 15.6 ºC, but during May the temperature recorded 
at day is 41.9 ºC and at night is 27.6 ºC. 
 (Metrological authority data sheet 2006) 
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            At the same time the majority of drug sealers (55%) have no 
transportation facilities and the majority of stores facilities are suffer from 
inadequate electrical supply; so care we must be taken about storage and 
transportation of pharmaceutical products in Sudan. 
 (Hussein A. H. august 2006)                   
        Dexamethasone sodium phosphate injection should be protected from 
light and dexamethasone tablets should be stored in well-closed containers. 
5.1. Results:- 
               The results of the present work for the studied dexamethasone 
different formulations were evaluated from the physical and chemical 
point of view. 
5.1.1.Injections:- 
                The samples show little change in pH and appearance of the 
solution. 
              The chemical analysis of the samples at zero time (seven month 
after manufacture date)gave results of  106.3% ±(0.0127) table (9).After 
8 month of distribution it showed 20% - 25% deteriorations in different 
areas of Sudan, compared to samples in the stability cabinet which 
showed 15% ±(0.00096) table (10)deteriorations this mean that the 
samples in pharmacies were exposed to storage conditions exceeded that 
found in the stability cabinet (30±2C˚and 65%RH).After one year all the 
samples showed 20%-30% deteriorations ,when these samples were 
compared with that one which was stored in well controlled conditions 
(C.M.S.) which the content % dropped from 106.3% to 103.12% after 
one year ,this can be considered as a reasonable change , this comparison 
indicate that the storage conditions in pharmacies play the main role in 
the observed deteriorations.   
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5.1.2. Oral solutions:- 
The samples showed little change in pH and physical appearance of the 
solution. 
                The chemical analysis of the samples at zero time (5 month 
after manufacture date) 100.2% ±(0.0084) table (23).After 4 month of 
distribution it showed 6% - 13% deteriorations in different areas of 
Sudan, compared to samples in the stability cabinet showed 5% 
±(0.0114)(table 24)deteriorations, this mean that the samples in 
pharmacies were exposed to storage conditions exceeded that found in 
the stability cabinet (30±2C˚and 65%RH). After one year all the samples 
showed 35%-37% deterioration, when these samples were compared with 
that one which was stored in well controlled conditions (company 
store)after one year it's content % dropped from 100.2% to 94.5% after 
one year ,this can be considered as a reasonable change , this comparison 
indicate that the storage conditions in pharmacies play the main role in 
the observed deteriorations.  
5.1.3. Tablets:- 
          The samples showed an increase in dissolution test reading after 4 
month(tables 15 - 20) which could be due to presence of the degradation 
product  which absorb at the same  wave length of the drug (the method 
is not selective).  
                The chemical analysis of the samples at zero time (11 month 
after manufacture date)  99.8 % ±(0.0162) table (12 and13).After 8 
month of distribution it showed 5% - 9% drop in different areas of Sudan 
included samples stored in the stability cabinet. After one year all the 
samples showed 7% - 13% drop. This mean the effect of storage 
condition in the tablets is less than that of injections.  
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            Comparison between tablets (from another company) stored in 
pharmacy and company stores were results the following; after 6 month 
both samples were showed about 14% drop, this means that the company 
store was not have adequate storage conditions(we use samples from 
other company because our samples which stored in the company store 
were missed) . 
5.1.4. Ointments:- 
         The samples showed no change in its physical state and appearance.        
        The chemical analysis of the samples at zero time (2Years after 
manufacture date)  110.6 %±(0.0151) table (21 and 22).After 12 months 
of distribution it show 1% - 10% drop in different areas of Sudan include 
samples stored in stability cabinet ,This mean the effect of storage 
condition in the ointment is less than that of oral solutions, injections and 
tablets.  
 From all of this we can say:- 
         1. The different dosage forms of dexamethasone (representing the 
drug substance) which stored in the real storage conditions in the market 
(pharmacies and ware houses) especially oral liquids, injections and 
tablets were become out of the USP limits long time before their expiry 
dates. This means that the circulating drugs are becoming of low qualities 
and possibility of toxic decomposition products that might lead to use of 
non effective and non safe drugs . 
2. The deterioration of some dosage forms stored in the stability cabinet 
may be due to:- 
2.1. The electrical supply disconnection from the cabinet during 
may/2008 for 15 days. 
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 2.2. The drug formula was not stable in storage conditions used for on 
going stability testing which recommended for registration.      
3. The dosage forms had very fast deterioration in their concentrations in 
the period between May and august (hottest seasons); this indicates that 
the storage conditions were not well controlled and monitored. 
5.2. Kinetic studies of dexamethasone stabilities:  
The stability study for different formulations of dexamethasone revealed     
a first order reaction figures (41, 42,43and44). 
The calculated rate of reaction, t10 and t50 were: 
? For dexamethasone sodium phosphate injection:  
K =0.693/ = 0.3118 
t10 =0.105/0.3118 = 0.3367 month 
t50 =0.693/0.3118 =2.2225 month 
For dexamethasone tablets: 
K =0.693 / 0.0055 =126 
t10 =0.105/126 =- 0.00083 month 
t50 =0.693/126 =-0.00 55 month 
For dexamethasone ointments: 
K =0.693 /0.0021 =330 
t10 =0.105/ 330 = -0.00031month 
t50 =0.693/330 =- 0.00 21month 
For dexamethasone oral solutions: 
K =0.693 / 0.0168 = 41.25 
t10 =0.105/41.25 =-0.00254 month 
t50 =0.693/41.25 =-0.0168month 
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5.3. Validation of the proposed ultraviolet method used for 
dissolution test for tablets:- 
5.3.1Sensitivity:- 
 The UV method was found to be sensitive when the results compared 
with that obtained from the same solution using HPLC method, that the 
ultraviolet absorption value (0.678-0.648) while the area under the peak 
obtained from the HPLC system (3.35-3.495). 
When the dissolution media was directly injected to the HPLC system 
the peaks obtained was so small and negligible.  
     The ultraviolet absorption for the dissolution media at 240 nm and 
254 nm was found to be weak compared with that of treated  dissolution 
media ,meanwhile the absorption value at 254 nm was found to be less 
than  0.1 . 
    5.3.2 Linearity:- 
The UV method was found to have linear relationship between the 
concentration and absorbance with regression value (R²) = 0.9998.  
5.3.3Limit of quantitation:- 
 The minimum concentration that can be detected using this UV method 
is 0.000003 g/ml (3 µg/ml). 
5.3.4 Selectivity:-  
 The UV method was found to be not selective, that it can not select the 
dexamethasone from other steroids and degradation products, so another 
method should be chosen . 
5.3.5Accuracy:- 
  The UV method was found to be accurate as the standard deviation of 
the actual results from the theoretical results were not more than 2.7%.  
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Chapter (7) 
Recommendations 
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1. The drug companies, stores and distribution facilities must be under 
strong control of the regulatory authority.   
 
2. The pharmacies storage conditions must be obligatory monitored and 
recorded and they have to leave the conditioning system acting all over 
the day (24 hours) or to keep drugs in the refrigerator. 
 
3. The regulatory authority must take strong punishments against any             
company gave unreal data about the stability of their drugs.   
 
4. Massive drug stability studies should be done on most of drugs that 
circulate in Sudan especially in areas out of Khartoum providence.  
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